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ABSTRACT 
Whole exome sequencing (WES) is a relatively new testing option, currently offered primarily in 
the pediatric setting, that is open to more uncertainty than single gene or gene panel testing. This 
uncertainty makes pre-test counseling challenging yet critical to ensure informed consent. 
Adaptation of counseling strategies for this type of testing requires a better understanding of 
parents' experiences throughout the WES testing process. However, the experience of parents of 
chronically ill children who have actually gone through the entire WES testing process has not 
been widely reported in the literature. Currently, analysis of exome test results at Children’s 
Hospital of Pittsburgh does not include the incidental findings that are typically reported in WES 
results (i.e. variants in genes that are not associated with the child’s present condition) and is, 
therefore, referred to as “targeted exome sequencing” (TES). This study was designed to gain an 
understanding of the psychosocial impact on parents of the TES testing process for chronically ill 
children in order to improve test education, consent and results disclosure processes, and to 
better help parents cope with the results. Semi-structured interviews were conducted with 11 
parents of children who received targeted exome sequencing results and thematic analysis was 
performed on transcripts generated from the interviews. The experiences and opinions of parents 
whose children received positive, likely negative or uncertain results were analyzed, in order to 
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develop a robust understanding of the full TES process. This study has Public Health 
significance because the results may contribute to the development of updated recommendations 
for optimizing informed consent and results disclosure for TES. 
 vi 
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1.0  INTRODUCTION 
Whole exome sequencing (WES) is a relatively new testing option currently used primarily in 
the pediatric setting and is open to more results uncertainty than single gene or gene panel 
testing. Counseling strategies must be adapted to adequately provide informed consent for this 
type of testing. Adaptation of counseling strategies requires a thorough understanding of parents' 
experiences throughout the WES testing process. A number of studies investigating individual 
experiences, opinions, and beliefs related to WES have been conducted in various populations. 
The subjects of these studies typically either involve parents of chronically ill children who have 
not undergone testing or relatively healthy adults who received testing by volunteering for a 
research study. Thus, these studies focused on hypothetical preferences. The majority of these 
studies focus on preferences for return of results and reasons for these preferences1–10.  
There remains, however, a dearth of literature exploring the experience, perceptions and 
beliefs of parents of chronically ill children who have gone through the entire WES testing 
process. It is unknown how parents’ views might change following results disclosure and how to 
best prepare them for multiple, uncertain outcomes. In order to tailor counseling to the unique 
needs of patients undergoing WES, a deeper understanding of parents’ experiences with WES is 
required. This understanding should include parents’ perceptions of WES and how these 
perceptions evolve throughout the testing process as well as parents’ opinions of the informed 
consent process and how prepared this process made them for the disclosure of results. 
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Currently, analysis of exome test results at Children’s Hospital of Pittsburgh (CHP) are 
“targeted” to the patient’s clinical presentation and does not include the incidental findings that 
are typically reported in WES results11 (i.e. variants in genes that are not associated with the 
child’s present condition). The results from targeted exome sequencing (TES) typically fall into 
three broad categories: (1) known pathogenic variants in a gene associated with patient’s 
condition (“positive” result), (2) a variant of unknown significance that might be diagnostic 
pending further developments (“uncertain” result), and (3) a variant of unknown significance that 
will likely never be diagnostic and is thus considered a "negative" result. It is important to 
consider the perceptions of parents in all three categories in order to develop strategies to prepare 
parents for any possible outcome. 
The present study used qualitative thematic analyses of semi-structured interviews to 
identify the perceptions, beliefs, and experiences of parents of chronically ill children who have 
undergone targeted exome sequencing.  A deeper understanding of their experience may help 
direct medical genetic practice in the informed consent process and disclosure of results. 
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2.0  RESEARCH QUESTIONS AND SPECIFIC AIMS 
2.1 RESEARCH QUESTIONS 
Question 1: What is the psychosocial impact on parents of targeted exome sequencing of 
chronically ill children? 
2.2 SPECIFIC AIMS 
Aim 1: To conduct semi-structured interviews with parents of children who received targeted 
exome sequencing results. 
Aim 2: To perform thematic analysis on transcribed interviews and develop a comprehensive 
understanding of the data. 
Aim 3: To contribute to recommendations for optimizing informed consent and results 
disclosure for targeted exome sequencing at Children’s Hospital of Pittsburgh of UPMC based 
on study findings. 
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3.0  BACKGROUND AND SIGNIFICANCE 
3.1 EVOLUTION OF GENETIC TESTING 
The etiological bases of at least 7000 genetic disorders are currently known.  While each is 
relatively rare, collectively their incidence is estimated to be 1/50 live-born individuals.  
Furthermore, with roughly 20,000 genes in the human genome, the number of known genetic 
disorders is likely to increase as more data becomes available.  In a recent analysis of 500 
unselected consecutive patients, it was reported that 46% of patients with unknown suspected 
genetic disorders receive a genetic diagnosis through traditional genetic approaches, while the 
remaining 54% do not receive a diagnosis12.  Traditional clinical genetics refers to a 
comprehensive genetics evaluation (pregnancy, family, developmental and medical histories and 
detailed physical examination) followed by targeted testing based on the evaluation.  Testing 
may include chromosomal studies, biochemical studies, single gene testing, gene panel testing, 
or microarray analysis.  Of those patients who did receive a genetic diagnosis through traditional 
genetic approaches, 72% were diagnosed during the first diagnostic evaluation12, suggesting 
WES or whole genome sequencing (WGS) as a second-line test might increase yield and 
decrease time to diagnosis thereby decreasing costs of subsequent testing.   
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3.2 WHOLE EXOME SEQUENCING (WES) 
3.2.1 Utility 
Whole exome sequencing (WES), first introduced in 2009, takes advantage of targeted exon 
capture and massively parallel sequencing capabilities to sequence almost all the coding regions 
of human DNA13,14 .  While the exome covers only 1% of human DNA, it accounts for over 85% 
of known genetic diseases.  Using Next Generation Sequencing technologies rather than relying 
on conventional sequencing methods, WES is able to sequence over 30Mb of DNA for a fraction 
of the cost and at greater speeds. Single gene or panel testing are still preferred clinical genetic 
testing methods when a specific disorder and/or a small subset of genes are suspected to cause 
the patient’s phenotype.  WES has been increasingly used clinically when the suspected 
condition is genetically heterogeneous or the underlying genetic cause is unclear15.  Because 
WES is the most comprehensive and unbiased genetic test currently available clinically, it is 
particularly useful for diagnosing rare Mendelian disorders or uncovering complex mutation 
patterns by sequencing thousands of genes at once.  
Most institutions report a 25-35% success rate in identifying pathogenic variants with 
WES.15–19 Patients tend to be referred for WES following extensive evaluations by geneticists 
and other specialists with testing that may include MRI/CT scans, muscle biopsies, metabolic 
panels, karyotype analysis, single gene testing, gene panels, chromosomal microarrays, and 
others depending on the indication.  Utilizing WES as a first line test, would likely result in a 
higher yield.  A recent analysis of the 153 exome cases that have been seen at Children's 
Hospital of Pittsburgh of UPMC (CHP) revealed a 39.2% diagnosis rate20.  
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The utility of the unbiased approach afforded by WES has been highlighted in a number 
of recent retrospective studies by the major clinical laboratories offering WES testing.  An 
assessment of 2000 and 3040 consecutive cases receiving WES through Baylor Miraca Genetics 
Laboratories (BMGL) or GeneDx, respectively, revealed that 37-41% of confirmed cases were 
due to de novo autosomal dominant variants, 29-34% were autosomal recessive, and 11-12% 
were X-linked15,19.  These confirmed cases corresponded to 25.2% of BMGL’s total WES cases 
and 28.8% of GeneDx’s WES cases.  Importantly, 3-4.6% of cases were found to harbor two or 
more pathogenic variants and BMGL reported that 58% of the total pathogenic variants 
uncovered had not been previously reported15,19.  Moreover, a study of 362 Canadian individuals 
receiving WES testing at the end of their diagnostic odysseys found that 29% had mutations in 
genes known to cause disease21.  The study reported that these mutations were not previously 
identified due either to genetic heterogeneity or an atypical presentation21.  These numbers 
suggest that traditional genetics approaches of single gene and gene panel testing were unlikely 
to determine the genetic basis for most of the cases included in the studies.   
The 5000 cases analyzed at BMGL and GeneDx revealed a high diagnostic yield for 
neurologic conditions (24.6%-36.1%) and multiple congenital anomalies (24%)15,19.  Other 
studies have shown the ability of WES to detect pathogenic variants related to 
neurodevelopmental disorders22, speech apraxia23, atrial septal defects24, skeletal dysplasias25, 
limb-girdle muscular dystrophy26, and retinal dystrophies27, to name a few.  In a post-hoc 
analysis of patients who received testing either through traditional Sanger sequencing or WES 
for similar indications, WES provided a significantly higher diagnostic yield for heterogeneous 
conditions such as blindness (52% vs 25%), deafness (44% vs 10%), and movement disorders 
(20% vs 5%)28. 
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3.2.2 Sequencing Method 
Currently, most WES protocols rely on solution-based methods for target enrichment18,29,30. To 
begin, a standard pool of biotinylated oligonucleotide baits with sequencing-platform specific 
adaptors is made against the target regions of 180,000 exons in the human genome.   The 
patient’s DNA sample is fragmented and allowed to hybridize with the biotinylated baits.  
Streptavidin beads are used to pull down the biotinylated bait-DNA fragment complexes while 
the unbound, non-targeted DNA fragments are washed away.  The pool of targeted fragments is 
next enriched through PCR amplification followed by high throughput sequencing.  Because 
WES relies on massively parallel sequencing methods, it is important to have sufficient read 
depth for each target in order to build an accurate and reliable consensus sequence. All 
participants in this study received testing through BMGL.  BMGL quotes a mean coverage of 
100-120X with 95% of the exome covered at a depth of at least 20X31.    BMGL also provides a 
WES coverage search tool for clinicians to determine whether specific genes included in their 
differential diagnoses are covered at sufficient depths to be meaningful for their particular 
patient.  This method for WES does not reliably detect triplet repeat expansions, copy number 
variations, long insertions/deletions, chromosomal translocations, aneuploidy, or epigenetic 
alterations31,32. 
3.2.3 Variant Interpretation 
An initial list of variants is identified by comparing the consensus sequence to a reference 
sequence.  In order to produce a consensus sequence, multiple overlapping reads are aligned and 
compared, generating a sequence that represents the most likely true sequence of the patient. 
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This consensus sequence can then be compared to a reference sequence, or a sequence used as a 
‘normal’ control. A read depth of 20 or more allows for interpretation of any reads that don’t 
match the reference sequence.  For instance, if a small proportion of the reads show a T at a 
particular position while the remaining reads have an A, the discrepancy can be attributed to a 
replication error and an A will be called for that position.  However, if 50% of the reads are T 
and 50% are A, the patient will be considered a heterozygote for that variant. By simply 
identifying the base pairs that differ between the consensus and reference sequence, the variant 
lists can contain on the order of 10,000 different variants32.  Filters must be applied to reduce the 
list to those variants that have a higher likelihood of being pathogenic.  Tools such as minor 
allele frequencies, mutation databases and, disease specific databases are used to filter out 
common variants that likely represent natural human variation29.  Still, most samples reveal 50-
150 ‘personal’ rare variants.  Board certified molecular lab directors, genetic counselors and 
medical directors then use clinical phenotype information to further narrow down the list to 
potential disease causing variants31. Data from parental samples, if available, can also aid in 
determining both pathogenicity and mode of inheritance.  Once a list of reportable variants is 
assembled, the variants are verified by Sanger sequencing in order to rule out false positives 
before finalizing the report. 
3.2.4 Reporting results 
Generally, when ordering WES from BMGL, clinicians receive a focused report with the option 
to also order an expanded report.  The focused report for WES includes results for pathogenic 
variants or variants of uncertain significance (VUS) in genes that are known to be related to the 
patient’s clinical phenotype.  It also includes information on any incidental findings such as 
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variants determined to be medically actionable by American College of Medical Genetics and 
Genomics (ACMG) and BMGL, carrier status, and pharmacogenetics, depending on what 
information the patient/parent choses to receive.  In 2013, the ACMG issued a policy statement 
regarding the reporting of incidental findings in clinical exome and genome sequencing11.  
Incidental findings typically mean variant discoveries that are not based on the patient’s current 
phenotype. This statement recommends actively searching for specific kinds of mutations in 
genes associated with 24 different conditions on the 'minimum list' compiled by the Working 
Group on Incidental Findings in Clinical Exome and Genome Sequencing.  Inclusion on this list 
was based on (1) the existence of standard methods to confirm a medical diagnosis, (2) long 
latency period in asymptomatic, pathogenic mutation carriers, and (3) availability of preventive 
measures and/or treatment.  Furthermore, the recommendation included a restriction on the types 
of variants reported to those that were categorized as “Known Pathogenic” or “Expected 
Pathogenic”. These terms would refer to “Pathogenic Variant” and “Likely Pathogenic Variant” 
under the updated ACMG Variant Classification Guidelines33.  Finally, the Consensus Statement 
recommended that reporting these incidental findings should not be limited by the patient's age, 
even though many conditions listed are adult-onset conditions.  Generally, genetic testing for 
adult-onset conditions is not offered to individuals under the age of 18.  However, the ACMG 
Working Group argued that since adults do not routinely have access to exome or genome 
sequencing technology at the current time, the potential harm to the future adult due to the loss of 
autonomy was outweighed by the potential benefit to the individual’s future health11. 
Since patients/parents undergoing WES must opt in to receive information on each 
category of incidental findings separately, the visit to discuss informed consent for the test can be 
quite extensive and time consuming.  After the clinician receives the focused report, there is the 
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option to order an expanded report, if felt necessary. The expanded report includes results for 
pathogenic variants or VUSs in genes unrelated to the patient’s clinical phenotype.  Clinicians 
generally rely upon the expertise of the testing company to determine what results are clinically 
relevant and therefore, included on the focused report.  However, in some cases, after receiving a 
negative focused report, a clinician may order the expanded report, rationalizing that he/she is 
more familiar with the patient’s clinical phenotype and wants to verify nothing was overlooked. 
Even with a focused WES report, most patients are typically found to have variants in 
multiple genes that could be related to some aspect of their clinical phenotype.   In silico 
prediction software lends evidence about the possible pathogenicity of the variants. It is then up 
to the ordering clinician to research the conditions associated with those genes to determine 
whether each is more likely or less likely to explain the patient’s phenotype.  WES reports rarely 
show completely negative results; typically, reports either contain one verified pathogenic 
variant plus a few VUSs in genes that are less likely to be causative, one or two very suspicious 
VUSs with or without a few less likely to be pathogenic VUSs, or a number of VUSs in genes 
that all appear unlikely to explain the patient’s phenotype.  When disclosing results, the clinician 
must be able to clearly explain the difference among known pathogenic, suspicious variant, and 
variant not likely to be related to the phenotype.  The distinction may seem quite ambiguous and 
be open to much interpretation on the part of the patient/parent. 
While such a comprehensive genetic test can provide unexpected yet explanatory 
answers, very often parents and patients receive unexpected yet uninterpretable results. As 
opposed to single gene or even gene panel testing, WES is open to more ambiguity and 
uncertainty, making pre-test counseling challenging but also critical to ensure informed consent.  
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3.3 TARGETED WHOLE EXOME SEQUENCING (TES) 
In collaboration with Baylor Miraca Genetics Laboratories (BMGL), the Medical Genetics 
Department of Children’s Hospital of Pittsburgh (CHP) recently developed a Targeted Exome 
Sequencing (TES) test in order to limit the number of incidental and secondary findings.  When 
submitting a test requisition form for whole exome sequencing, clinical notes including a full 
description of the patient’s symptoms, characteristics and family medical history are sent along 
with the blood sample.  As part of the data analysis after performing WES on the patient’s DNA, 
an additional filter to exclude any genes unrelated to the patient’s clinical presentation is applied.  
Therefore, the final report is ‘targeted’ to include only those variants in genes that overlap with 
the patient’s phenotype.  Additionally, variants in the ACMG Recommended List of Incidental 
Findings11 are not included in TES reports at CHP and there is no option for an expanded report.  
Since the results are targeted based on the patient’s clinical phenotype and there are no additional 
incidental finding options that require an opt in, the time spent in pre-test counseling is greatly 
reduced.   Parents are informed of this limitation of TES testing during the consent process. 
3.4 GENETIC COUNSELING PROCESS AT CHILDREN’S HOSPITAL OF 
PITTSBURGH OF UPMC 
3.4.1 Genetics visits prior to targeted exome sequencing  
In the majority of cases, patients who eventually receive TES have multiple genetics visits prior 
to receiving TES.  Whole exome sequencing is not typically considered a first line genetic test, 
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therefore, the more readily testable genetic conditions often are ruled out first based on suspected 
diagnoses given the individual’s phenotype before exome sequencing will be offered. Beginning 
in December 2013, CHP instituted an algorithm for molecular testing.  Single gene tests are 
considered first if the patient’s symptoms suggest a specific genetic condition.  If a single gene 
test is not ordered or if no mutations are found, then a SNP microarray is pursued.  Next, if the 
SNP microarray results do not explain the patient’s clinical presentation, symptom specific gene 
panels are then considered.  Finally, if the gene panel does not return any pathogenic mutations, 
WES/TES may then be pursued.  Most parents of children who receive TES have some prior 
understanding of genes and chromosomes due to this exposure to genetic testing but are 
unfamiliar with more complex concepts such as exome sequencing.  When TES is first offered to 
parents at CHP, either a genetic counselor or geneticist provides a brief overview of the process 
and the types of possible results, including positive, uncertain and uninformative/negative.  
Parents are told ahead of time that positive results are returned in 30-40% of cases and that it can 
take up to six months to receive results following insurance approval.  The genetic counselor is 
available to answer any questions after the introduction to TES but there is no formal 
presentation introducing parents to the details of exome sequencing and no materials are 
provided at the time of testing. 
3.4.2 Targeted exome sequencing results disclosure visit 
CHP works with one counselor affiliated with BMGL whose role is solely dedicated to analyzing 
and disclosing exome results.  For each results disclosure visit, she prepares a detailed handout 
describing genes, chromosomes, and TES followed by a meticulous description of each variant 
identified, an assessment of what those variants mean for the patient, and any follow-up 
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recommendations possible.  The handout is then given to the parents to take home for their 
reference along with a copy of the original report.  A letter summarizing the visit and the results 
is sent to the parents and any physicians as requested by the parents.  The counselor is then 
available by phone and email for any future questions.  
3.5 PUBLIC PERCEPTION OF WHOLE EXOME SEQUENCING  
A number of studies investigating individual experiences, opinions, and beliefs related to WES 
have been conducted in various populations. The subjects of these studies typically either involve 
chronically ill children who have not undergone testing or relatively healthy adults who received 
testing by volunteering for a research study, thus they focused on hypothetical preferences.   
3.5.1 Parents of affected children hypothetically considering whole exome sequencing 
The majority of these studies focus on preferences for return of secondary findings and reasons 
for these preferences.  For instance, a qualitative study of 25 parents of 13 probands with rare 
genetic conditions asked participants about their motivations for return of results preferences if 
they were offered WES testing34. These participants did not go through the informed consent 
process for WES nor did their children receive WES testing.  The majority of subjects provided 
either positive or neutral responses to questions about receipt of results indicating carrier status 
for recessive conditions as well as both treatable and untreatable childhood conditions.  The only 
negative responses were generated regarding receipt of secondary variants for untreatable 
childhood conditions. A number of themes emerged from the analysis of semi-structured 
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interviews including, parental responsibility to find answers for their children, preference for 
knowledge, control over genetic information, and altruism34.  
In a focus group study of parents whose children have suspected genetic conditions and 
could potentially be offered WES, parents raised concerns about stigmatization, insurance and 
employment discrimination, loss of privacy and restrictions on their child’s future reproductive 
decision making. However, parents would still pursue testing because results could have 
therapeutic benefit and could help elucidate disease course. Concerns about the limitations of 
WES were not mentioned. Parents wanting all results to be disclosed, including incidental 
findings, mentioned entitlement to their own genetic information and possible future utility as 
reasons. Having results for conditions unrelated to their child’s current clinical presentation may 
be therapeutically beneficial if there are treatments, therapies or preventive methods available 
now or in the near future.  These parents would also prefer to receive results for adult-onset 
untreatable conditions because they place value on the ability to prepare and to know what to 
expect35.   
Importantly, parents revealed that the strong desire for a diagnosis and prognosis for their 
child would likely lead them to pursue WES without fully contemplating the consequences of 
secondary findings35.  As mentioned above, parents raised a number of concerns regarding WES 
beyond that of secondary findings and yet all would pursue testing.  The potential to end the 
diagnostic odyssey seems to override any other trepidation these parents may have about exome 
sequencing, which highlights a possible barrier to informed consent.  Parents also conceded that 
the complex nature of exome sequencing could further challenge and complicate informed 
consent because parents may not sufficiently understand what the test can and cannot do.  This 
lack of understanding could lead to misplaced expectations and/or misinterpretations of results.  
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It is unclear how well parents are able to adequately consider the potential impact of pursing 
WES when a singular focus to find a diagnosis and a limited understanding of a complex test 
may prevent parents from appreciating both the pros and the cons of testing. 
3.5.2 Adult volunteers in Whole Exome or Whole Genome Sequencing research projects 
ClinSeq is a large pilot study of >1000 participants aimed at optimizing the use of clinical whole 
exome and genome sequencing to improve patient care36. One of the study goals is to “establish 
approaches for informed consent and the return of genetic information to subjects”36.  The 
ClinSeq group has published a number of studies investigating the experience of participants 
with WES/WGS and their preferences for the return of results2,9,37.   
Recently, the perceived value of WGS results was surveyed among 320 ClinSeq 
participants2.  Subjects were questioned about the value of receiving results related to treatable 
conditions, untreatable conditions, carrier status and VUSs.  Overall, the majority of participants 
valued all 4 types of results, even uninterpretable ones, although those providing information on 
treatable conditions and carrier status were valued more highly.  In addition to medical utility, 
participants placed value on knowledge, the impact on increased health awareness, and the 
ability to inform family members2. 
A recent study of ClinSeq participants investigated the perceived utility of WES results 
for individuals who received urgent and actionable secondary results38.  Most of the 31 
participants in this qualitative study received results pertaining to either cardiac or cancer risks.  
Responses to receiving results were largely positive or neutral with negative responses 
uncommonly expressed.  Participants conveyed relief that the implications of the results were not 
more serious and that there were adequate surveillance options available.  The experience with 
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genetic counseling and receipt of WES results also induced a general increased awareness of 
health in participants who then pursued more healthy living practices.  Participants also found 
personal value in the results in that they provided an answer for certain health issues running in 
the family or in that they satisfied curiosity.  Generally, the participants in this study were self-
referred, early adopters of technology and over 60 years of age38.  
3.5.3 Parents of children undergoing clinical whole exome sequencing 
Recently, two qualitative studies investigated the experience of parents whose children received 
whole exome sequencing in an attempt to diagnose their chronic conditions39,40.  In both cases, 
WES was offered as part of research study rather than in a clinical genetics setting.  One study 
explored the expectations, understanding, utilization of results, and communication of findings of 
19 parents of children who underwent WES40.  Parents’ interest in WES was driven by a sense of 
duty to pursue any course of action that will lead to a diagnosis for their child.  Even though they 
felt this duty to find answers, parents expressed fear that WES would uncover a lethal diagnosis.  
While parents hoped for a diagnosis, their expectations of WES were moderated by prior 
experiences.  For those that did receive a diagnosis, some remained frustrated with sense of 
isolation due to limited information about their child’s newly diagnosed rare disorder40. 
 Another study sought to evaluate a novel counseling strategy designed to mimic a 
possible future in which WES is part of standard diagnostic routine and counseling is performed 
by physicians, not genetic counselors39.  This study involved children with undiagnosed 
neurological disorders and neurologists performed pre-test and post-test counseling.  In their 
protocol, pre-test counseling was performed in clinic but test results were disclosed by telephone.  
Parents were then referred to a website with information specific to their child's diagnosis. An 
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appointment could then be made if parents wanted to discuss results further. Most parents in this 
study expressed a preference for an in-person results disclosure and prefer the hospital initiates 
the follow-up consult rather than leaving it up to the parents.  Furthermore, parents expressed a 
desire to be kept informed about the progress of testing during the wait for results. Upon 
receiving the results, parents are most interested in discussing what the results mean for their 
child’s care and they also articulated a need to share questions and concerns with health care 
providers to deal with practical and psychosocial problems.  Finally, one requirement to 
participate in this research study was that participants had to accept the receipt of incidental 
findings. Some saw value in obtaining extra health information but others want to be able to 
decide for themselves whether or not to receive this information39.   
While these studies provide insight into the public perception of WES in hypothetical or 
research settings, the experience of parents whose children have undergone WES in clinical 
settings has not been adequately explored in the literature.  It is unknown how parents’ views 
might change following results disclosure and how to best prepare them for multiple, uncertain 
outcomes.  In order to tailor counseling to the unique needs of patients undergoing WES, this 
study seeks to gain a deeper understanding of parents’ experiences with WES. This 
understanding includes parents’ perceptions of WES and how these perceptions evolve 
throughout the testing process as well as parents’ opinions of the informed consent process and 
how prepared this process made them for the disclosure of results.   
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4.0  DESIGN AND METHODS 
4.1 PARTICIPANT SCREENING AND RECRUITMENT 
4.1.1 Ethical considerations 
The Institutional Review Board of the University of Pittsburgh approved this study 
(PRO15030727 – APPENDIX A).  Informed consent was obtained from all participants. 
4.1.2 Inclusion criteria 
Participants were recruited from parents of children who received targeted exome sequencing 
test results and who then consented to participate in interviews. 
4.1.3 Exclusion criteria 
Because this study requires in-depth interviews, any participants who met the inclusion criteria 
but were not fluent English-speakers were excluded from participation.  Participants with 
intellectual disability were also excluded. 
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4.1.4 Screening Procedures 
Screening of potential participants was based on results of targeted exome sequencing (TES). 
Marianne McGuire, a Baylor College of Medicine (BCM)-affiliated Genetic Counselor 
specializing in TES, compiled a list of eligible participants according to the stated inclusion and 
exclusion criteria. Since she was already familiar with the patients' medical records, she 
categorized the potential participants as parents of children who received either definitively 
positive, likely negative, or uncertain results from targeted exome sequencing. Ms. McGuire 
contacted the eligible participants to introduce the study to the potential participants by briefly 
describing the study goals, risks and requirements. The participant could then agree or decline to 
either contact the PI or allow the PI to contact the participant. The goal was to recruit participants 
until we had 5 participants in each category. The members of the study team did not access the 
medical records of the potential research participants or their children and were not informed of 
any specific test results. 
4.1.5 Participant Recruitment 
Eligible participants who agreed to be contacted were consented by telephone. Verbal informed 
consent was obtained following an explanation of the rationale, goals and design of the proposed 
research and consent for one-on-one semi-structured interviews. Individuals could choose to 
consent to research immediately, to consider it further and consent at a later date, or decline to 
participate. If participants chose to think about participating, the participant and contact person 
discussed a mutually agreeable date and time for re-contact. Following the informed consent 
process, a mutually convenient time to conduct the interview either in a private room at 
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Children’s Hospital of Pittsburgh or by telephone was chosen. Recruitment was based on 
whether the children received positive, likely negative or uncertain results. We continued to 
recruit participants until we had 5 participants in each category. Refusal to participate in this 
study did not affect their child's continued medical care.  Participants were not compensated for 
participation.  Seventeen participants were contacted for participation in this study.  Thirteen 
provided informed consent for participation and 11 completed interviews with the researcher.  
Two participants withdrew after providing informed consent due to scheduling conflicts and 
initial contact was not made with 5 potential participants despite two attempts to contact them by 
telephone per the Institutional Review Board-approved protocol.   Two of the interviews were 
performed in person and the remaining nine were conducted by telephone.  One of the in-person 
participants was accompanied by her husband and child.  The husband was consented on site so 
he could offer comments as well but he did not undergo a separate interview and their joint 
interview was analyzed as one participant. 
4.2 PARTICIPANT INTERVIEWS 
Participants were interviewed by telephone or in person between September 2015 and December 
2015 by Bess Wayburn, a Genetic Counseling Intern with a PhD in Molecular Genetics, and 
supervised by a licensed, board-certified Genetic Counselor. Consent to participate included 
permission to record and transcribe interviews to maintain accuracy. Both the recordings and 
transcriptions were coded to protect the participants’ identities and these were maintained on 
password-protected computers in card-access only locations. A semi-structured interview guide 
was developed to gauge parental perception, expectations and experience with the entire targeted 
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exome sequencing testing process, including test education, informed consent, and results 
disclosure (See APPENDIX D for interview guide).  Initial drafts of the interview guide were 
reviewed by Ms. McGuire as well as by two members of the thesis committee with experience in 
qualitative research (RG and CWV).  Their input was incorporated into the final guide used in 
this study.  Each interview lasted approximately one hour. Interviews are reviewed, transcribed 
and coded as each was completed. Consistent with a qualitative approach, analysis began before 
all the interviews were conducted and later interviews were informed by earlier interviews.  This 
means that new lines of questioning could be developed based on early responses that led to a 
deeper exploration of parents’ experiences and perspectives. Upon completion of each primary 
interview, participants were requested for permission to re-contact by the interviewer in the event 
that early analysis uncovered topics that necessitated further exploration. All participants agreed 
to this request, however, based on their responses, it was not deemed necessary to re-contact any 
participants.   
4.3 THEMATIC ANALYSIS 
A wide variety of methods have been developed and employed in the field of qualitative 
research.  Thematic analysis, one widely used qualitative method, is a flexible and easily 
accessible method that is used to describe patterns (themes) across a qualitative data set.  Braun 
and Clarke further define thematic analysis by three different parameters:  (1) the method can be 
realist, constructionist, or contextualist, (2) analysis can be inductive or theoretical/deductive, 
and (3) themes can be semantic or latent.  The realist method focuses on a direct reporting of 
participants’ experiences, perceptions and beliefs while the constructionist method examines 
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how the wider social context constructs those experiences.  The contextualist method considers 
the reality of participants’ experiences, the meanings they attach to them, and the broader social 
context.  When performing inductive analysis, themes are developed from the content of the 
data.  Theoretical data analysis, on the other hand, develops themes from existing concepts. 
Finally, semantic themes explicitly reflect the data whereas latent themes describe underlying 
concepts.  Realist methods tend to cluster with inductive analysis and semantic theme 
development while constructionist methods cluster with theoretical/deductive analysis and latent 
theme development.   
This study was developed to obtain a deeper understanding of parents’ beliefs, 
perceptions and experiences with targeted exome sequencing.  Therefore, our approach followed 
the constructionist method with inductive analysis and development of latent themes.  Using this 
approach, we considered the reality of TES testing as well as the broader context in which 
parents’ experiences and the meanings attached to them were formed.  Using this approach, we 
intended to fill gaps in the literature and direct further research in this field. 
The thematic analysis approach used follows six steps.  While listed sequentially, the 
steps are performed through an iterative process where codes and themes are developed 
following initial familiarization with the data, the development of codes and themes leads to 
greater familiarization with the data and further refinement of the codes and themes.  In addition, 
analysis begins after the first interview is completed and this early analysis is used to inform the 
remaining interviews.  In this way, experiences that are revealed can be explored more deeply 
throughout the interview process.  The six steps to thematic analysis as proposed by Braun and 
Clarke are as follows: 
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1.  Familiarization with the data
2. Generation of initial codes
3.  Searching for themes
4.  Reviewing themes
5.  Defining and naming themes
6.  Writing the report  
4.3.2 Familiarization with the Data 
Each interview was reviewed in full at least once soon after recording and before transcribing in 
order to develop a deeper understanding of the experience and emotion expressed by the 
participants.  The majority of the interviews were transcribed by the investigator, which also 
increased familiarity with the data. A medical transcriptionist was contracted to transcribe a 
subset of the interviews. Whether transcriptions were transcribed by the researcher or by a 
transcriptionist, the documents were reviewed thoroughly by the researcher while listening to the 
original audio recording, prior to starting the coding process.  Any incorrect or missing parts of 
the interview were then resolved. Finally each transcript was read completely at least once more 
before coding began in order to develop a holistic understanding of each participant’s 
perspective. 
4.3.3 Coding the Data 
Transcripts were coded by the researcher in Microsoft Word® using Comments to highlight each 
code.  Use of comments allowed for the codes to remain linked to the parts of the transcript to 
which they refer for reanalysis and for extracting relevant quotes. Initial codes remained true to 
 24 
the participant’s language in order to preserve nuance.  A codebook was assembled in Microsoft 
Excel® based on the interview guide and iteratively revised following review and input from two 
co-authors experienced in thematic analysis.  An initial set of 1273 codes were identified from 11 
hour long interviews.   
4.3.4 Theme Identification 
Boyatzis (1998) defined a theme as “a pattern in the information that at minimum describes and 
organizes the possible observations and at maximum interprets aspects of the phenomenon” (p. 
161). The process of theme identification began by condensing the 1273 codes into broader 
categories.  Categories were assigned a separate column in the Excel® codebook in order to 
maintain the connections between the codes and the corresponding text.  Using Excel®, the data 
could be re-sorted by category and the codes assigned to each category could be easily re-
analyzed in this context.  Categories were reviewed to ensure the codes assigned complement 
each other and that each category represented a distinct idea41.  Codes were reassigned to other 
categories, categories were condensed, and new categories were created based on recursive 
review.   Themes began to emerge when considering the coherence of these categories across the 
full data set41.  When sorting by category in Excel®, it is also possible to quickly identify how 
many participants were coded for within that category and to which group they belonged.  If a 
category appeared highly representative of a shared experience across interviewees, it became a 
strong candidate for further theme development.  If a category did not demonstrate a common 
experience, the codes and data source were re-explored to determine if there is meaning in the 
dissonance or if the category is simply not relevant for the entire data set41. A category that 
represented a compelling experience relevant to the research question or that held implications 
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for genetic counseling practice was also a strong candidate for theme development regardless of 
its frequency among the participants. Additionally, as potential themes were developed, the data 
set was reviewed again to be certain codes were not missed during the early stages of analysis.  
Finally, themes are refined and defined by determining their scope, focus and narrative41. 
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5.0  RESULTS 
5.1 DEMOGRAPHICS 
All participants in this study were female and all but two are currently married.  Out of the 11 
participants, five had a child with a positive TES result, three had a child with an uncertain 
result, and 3 had a child with a likely negative result.  There was a wide range in years from 
onset of symptoms prior to TES spanning from 3 to 24 years with an average of 10 years.  
Participants were generally well-educated with five participants completing Master’s Degrees 
and all who reported had completed at least a high school education. 
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Table 1: Demographics 
Participant 
ID 
Result Years 
from 
Symptoms 
to TES 
# of other 
children 
Education 
Level of 
participant 
Marital 
Status of 
participant 
Gender of 
participant 
TES01 Positive 24 1 Masters Married Female 
TES02 Positive 4 2 Masters Divorced Female 
TES03 Positive 3 1 Unknown Married Couple 
TES04 Positive 13 1 Masters Married Female 
TES05 Positive 9 2 High 
School 
Married Female 
TES07 Negative 8 2 High 
School 
Married Female 
TES08 Uncertain 12 1 Unknown Married Female 
TES09 Negative 13 0 Unknown Married Female 
TES10 Negative 8 1 Masters Divorced Female 
TES12 Uncertain 8 1 Bachelors Married Female 
TES13 Uncertain 8 2 Masters Married Female 
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5.2 THEMES IDENTIFIED IN THE ANALYSIS 
5.2.1 Managing expectations 
All participants voiced understanding that the chance of getting an answer from TES was low 
and were appreciative that their expectations were managed prior to performing the test.  Still, 
even with this understanding, all hoped for an answer and there were wide differences in what 
participants actually expected.  For example, one participant expected an answer because the test 
was new and because of the extent of her child’s symptoms:   
“I was expecting them to find something, because of how just, they seem to test 
everything.  And it was new; I expected them to find something to answer what was going 
on with her.  But I was scared to know what it was.  But I did expect, with all the 
symptoms she has, and you know, I was expecting to find out something new.” (Negative) 
Others expected no answer based on their prior experience with inconclusive genetic testing. 
“Honestly, I wasn’t hopeful because she had not been diagnosed before.   I wasn’t 
thinking that there would be an answer.  I thought that it might be an inconclusive again 
but I was, I would like to know.  I was hoping that it would turn out to give us some 
answers but I wasn’t sure that it would.  I wasn’t convinced that we definitely would get 
an answer.” (Positive) 
 
“I went in with no expectations. …  Just because nothing, to my knowledge, had shown 
up before.  Even though I know what I know about the exome, I just…. You know, when 
you’ve been told for, geez it was 7 years at that point… 8 years – what you’ve been told 
for 8 years: this is the way your daughter is and we don’t know why she is the way she is.  
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You know, you just get used to hearing that.  So I just expected to hear again, we still 
don’t know why she is the way she is and maybe down the road with the advancement of 
medical science we can find something out – that’s kind of what I expected to hear.” 
(Uncertain) 
Due to the amount of analysis involved, exome results typically take up to 6 months to be 
returned.  Managing expectations regarding the wait time, therefore, was another crucial part of 
anticipatory guidance.  All parents understood how long the return of results was expected to 
take, however, the actual experience of waiting varied widely among participants from surprise 
the results came back as quickly as they did to them taking a seemingly interminable expanse of 
time: 
“I was actually surprised.  You know, I don’t know if I blocked that out for a while and 
didn’t think about it.  I just thought with how amazing that test was that I figured it 
wouldn’t be really quickly for us to get it back anyway.” (Negative) 
For one parent in particular, who eventually received a positive result, the wait “seemed like it 
was forever. It probably wasn't.  … It was six months.  Just under six months.” Part of the 
struggle with waiting was due to this parent’s constant worry over the different possible 
diagnoses that could be made.  Other parents were better able to put these thoughts out of their 
mind, making the wait more bearable: 
“They’re pretty punctual with their timing.  So it was ok because I just figured, you can’t, 
stressing over this stuff isn’t going to change it. You can’t do anything about it so just 
deal with it as it comes.  So we were all right.”  (Positive) 
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“Honestly as soon as we had the blood work done, I knew it was going to take a few 
months so I put it out of my mind other than just making the mental note that by June or 
July I had thought we should have the results back.  So at that time, I was like oh hey, we 
haven’t heard anything yet, I wonder what’s going on.  So, you know, I didn’t really think 
much about it until I knew it was time to be getting results.” (Negative) 
Even for those parents waiting furtively for results, participants seemed to understand that the 
complexity of exome requires time-consuming analysis.  Parents were also buoyed by their prior 
experiences with waiting for genetic test results and by the willingness to wait for answers if it 
means the analysis is thorough and correct: 
“The wait, when they finally did it that was hard.  It took a long time for the results and I 
can imagine what they would have to do to interpret those results.  I can't imagine how 
many hours were spent just on his one test.  But waiting, it’s like forever.  That is like a 
trip you would like to make just to hug someone.  [Laughter].  For all of those hours 
invested.” (Positive) 
“Well, you know what, we’ve done this so many times that it really wasn’t.  I mean this 
isn’t the first test; our last one wasn’t quite that long, but it’s not the first test that we’ve 
had to wait for. So as much testing and stuff that we’ve been through, for me it really 
wasn’t… I mean it kind of stinks because you want to know, but I understand that it’s a 
necessary time period to go through all that, I mean they’re going through a lot of data. 
And I’d rather them take their time and do it right, than rush it to get me back an answer. 
So I’m OK with the waiting. I mean it sucks, but I’m OK with it.  Because I want it to be 
right.” (Uncertain) 
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Interestingly, all participants felt exome met or exceeded their expectations and would do 
it again – even those who did not get answers and were previously frustrated by or found no 
meaning in prior experiences with genetic testing. One participant whose child received a 
positive result from TES, for example, described prior genetics visits as “Empty. Not very 
helpful.  They didn’t offer [anything] useful, which is why I don’t think that there was any...any 
need for us to continue to think about going back to them.  There was nothing useful coming out 
of that.”  Another parent expressed frustration over the repeated testing for single genes to rule 
out conditions that are more common but that the physicians didn’t really think explained her 
child’s clinical phenotype.   
“What I think was always so frustrating about that was ‘let’s put her through a blood test 
for something that we don’t think it is’.   And we really felt like she was being treated as a 
test case more than really trying to find what’s going on with her. … I think what 
bothered us so much is that a lot of the time, the doctor would say ‘we’re gonna test for 
this but we don’t really think that’s what it is – we just want to rule it out’.   And it was 
like they didn’t understand what an effort it was just to get the testing done in the first 
place. … It’s hard to have to restrain her and it’s physically difficult to restrain her so it’s 
been… it’s been emotional to say the least. “   (Uncertain) 
Parents, including those who were previously frustrated by the genetic testing process, expressed 
positive reactions to TES partially because this is the most extensive test currently available. 
With or without an answer, parents felt they have done everything they can at this point to help 
their child.   
“I think that it’s definitely something where if you have a child up there with all these 
question marks, I would tell any parent to do it just because whether or not you still come 
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back with question marks, you still know that you’ve exhausted all these resources that 
are out there for your child and not just sitting back and not trying to help.”  (Negative) 
Parent satisfaction with TES also extends from the counseling experience itself.  Parents voiced 
appreciation for delivery of information in a clear, concise, and thorough manner, attending to 
parents’ questions and concerns without feeling rushed, and providing materials to review at 
home and share with others.  One issue that many participants raised, though, was the concern 
for information overload during the results disclosure visit.  Results disclosure typically includes 
a review of genes, chromosomes, and the TES process in addition to discussing the relevance of 
each variant identified.  For some participants, trying to understand genetics while processing the 
meaning of their child’s test result was overwhelming.  These parents would like more 
information about basic genetics and the TES testing process prior to results disclosure either in 
the form of a brochure or links to trusted websites so they can study the background while 
waiting for results and feel better prepared:   
“Very overwhelming! To get all that information at one time.  So having the ability to 
have that information ahead of time may have made that a little bit easier ‘cause then we 
could have concentrated on just that [variant].”  (Uncertain) 
 
“To have to sit and kind of process everything and luckily she makes a really nice packet 
because there is just...me anyways, I was just kind of emotional and then to have to 
actually focus and pay attention to everything that she’s telling us because she walked 
through the whole process, broke down things in diagrams, so thankfully we had those 
things to take home with us to kind of work through even in the days after to look over.   
We emailed her a few times after we got home about different questions that kind of came 
after the fact.  It was a little overwhelming to say the least.”  (Positive) 
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Another parent, however, did not see the utility of receiving more information on TES upfront 
because the complexity of exome sequencing precludes non-genetics professionals from truly 
understanding its fundamentals.  This parent preferred to place her faith in health professionals to 
determine an appropriate testing strategy: 
“We were just glad.  Do what you need to do.  That is really what it comes down to.  I 
think they do a nice job of explaining, but again, you are talking about such specific 
knowledge set.  No matter how hard they try to explain it or go into detail, I don’t think 
the average person is going to get it.  I think that we just have to have faith that based on 
our awareness as a parent and conversations that you’re having, that the correct tests 
are being selected.”   (Positive) 
Others were not overwhelmed at all and expressed appreciation for the in depth results 
disclosure.  For instance, one parent in the positive category when asked if she felt overwhelmed 
during the results disclosure remarked, “No, no.  I was just intrigued.”  While another parent in 
the negative category conceded that the information presented during the results disclosure was 
“a little over our heads”, she still did not see the need for more information prior to that visit.  
5.2.2 Living with uncertainty 
One of the major themes to emerge from this research was that of living with uncertainty.  
Feelings of uncertainty were pervasive both prior to and following TES regardless of whether 
patients received a definitive or uncertain answer.  Prior to TES testing, participants in all groups 
expressed uncertainty regarding a diagnosis and all participants were most concerned with the 
uncertainty around life span.  Regardless of the outcome, participants described complex 
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relationships with uncertainty throughout their diagnostic odyssey, often finding a mixture of 
frustration, fear, meaning and comfort in the ambiguity.  
For instance, as one mother whose child eventually received a diagnosis following TES 
described, it was clear early on that there was something not quite right with her son but doctors 
could provide neither a diagnosis nor a prognosis: 
“[Our doctor] felt that there was a genetic condition, he just didn't know what it was and 
felt that all of these things including the seizures, the tremors, the failure to thrive, being 
small, his characteristics... he felt that...the way he explained it was that just all fell under 
this umbrella.  He just wasn't certain as to what the umbrella was.”  
Without an answer, various conditions are continually added to the differential diagnosis leading 
the parents to continually investigate each in an attempt to reconcile the uncertainty.  
Additionally, TES results often take up to 6 months to be returned.  An extended wait for 
answers can leave parents trying to prepare themselves in advance by researching all possible 
outcomes online.  As this mother continues to relate, having access to information without 
knowledge can be detrimental to a parent’s psychological wellbeing:   
“A hundred different things go through your mind.  You get on the internet and research 
all of these characteristics.  Some of the syndromes are pretty awful…pretty awful that 
they mention. So along the way you still have all of your regular doctor's appointments 
and check-ups and follow-ups with everybody.  They all mention something different, so 
of course, you are looking these things up, which does more harm than good.   It was just 
the unknown, the uncertainty.   You didn't want to be disappointed by no answer, but then 
on the other hand, you were fearful of getting an answer.  What happens if it's something 
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that is terrible, that’s just devastating, that’s awful?  You kind of psych yourself out and 
probably scare yourself more than what you need to.”  
This mother’s child, similar to all the cases who received positive results in this study, was found 
to have a rare, de novo pathogenic mutation.  Most of the conditions associated with mutations in 
these genes were newly characterized without much research. While receiving a diagnosis 
alleviated some pre-existing uncertainty, the rarity of the associated condition preserved that 
which remained. Parents now had an answer but most did not know what it meant for their child. 
The incomplete removal of uncertainty generated complex emotional responses to receiving a 
positive result in this participant: 
“I was devastated and relieved.  …  Now I know what it is and what's entailed.  How do I 
treat it?  How do I fix this?  But then your heart, this is your little guy that you love more 
than anything and you are telling me that he has this syndrome that you don't know 
anything about.  So that was hard too.  Just that immediate uncertainty.  I want to know 
exactly what it is.  The question that just even today is just the longevity.  I don't like … 
not knowing the life expectancy or longevity.  What can we predict?  So it was just 
emotionally overwhelming. … that uncertainty of longevity is probably the hardest part 
for me...not knowing.  What is the life expectancy for these children?  There are so many 
different variations of them that it is hard for them to tell.  They can't really give you an 
answer. … That part is probably the worst part for me.  He is happy and fairly healthy 
otherwise and it's just that longevity aspect that I am having a hard time with.”     
Nearly all participants in this study similarly placed life expectancy as their primary 
concern when faced with an uncertain prognosis, as echoed by another parent who said, “I would 
take anything as long as you tell me for whatever reason it is that my son is not going to have 
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short lifespan.  We can deal with it.  We will make it work.”  However, once her main fear of a 
shortened lifespan was alleviated upon learning of her child’s positive result, the remaining 
symptoms and issues that accompany this diagnosis predominated.  No longer paling in 
comparison to pre-mature death, the newfound weight of these concerns created an emotionally 
complex reaction. 
“My first question was: is there a short life span?  She said no.  I was so happy, so 
obviously there were more emotions.  Then you realize like the end result is I wanted to 
hear that my son will live a fairly healthy life and not have a short life span, but now we 
have to face all this.  You go from excited, to happy to sad all in a matter of one hour.”  
Conversely, parents whose children did not receive a definitive diagnosis from TES cited 
continued uncertainty regarding life expectancy as a positive outcome.  As explained by one 
participant: 
“This way we just have our normal life even if it’s not normal for others.  It’s our life and 
it’s scheduled and organized and we view things importantly in that way and I think in 
that respect, I think it’s kind of good not to know.  I know our lives would be radically 
different if we knew, especially if it was something that we only had a few more years. I 
think that would plague you and I think that would make you miserable. And I would 
think every time they would cough or they would sneeze you’d be freaking out thinking ‘is 
this it??’  You know, I don’t think I’d want that.  So in some ways, maybe not having 
answers is better too.  Even though it seems contradictory but…” 
Likewise, participants who did receive a positive result from TES recognized the 
psychological benefits uncertainty can provide and somewhat lamented its loss: 
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“We were much better off getting an answer, but it was hard getting an answer.  If we 
wouldn't have gotten an answer we could have said oh, you know, maybe it's nothing.   
Maybe he is going to outgrow whatever it is, but when you get an answer it's just like ok 
it’s in black and white.” 
Another parent whose child received a positive result from TES similarly described potential 
limitations that may have been placed on her daughter had there been a firm diagnosis earlier: 
“I think one of the benefits that I had in not having a firm diagnosis was that I had no 
reason to not think that she could not develop further, grow more, become over time, 
overcome some of her challenges, and just gave it a lot of space to work its way out. Now 
I can be comfortable with, I think I know who [my daughter] is, I know what [my 
daughter]’s going to need in the future and I can be ok with that.”    
This same parent, however, also recognized the potential benefits that may have been possible 
with more targeted therapies and interventions had a specific diagnosis been made earlier: 
“I think if we had the genetic testing and we knew this when [our daughter] was just a 
baby we wouldn’t have had sort of this wait and see how things go - what is the label 
going to be.  And I don’t really care about the label just accessing the resources, 
understanding what the needs are and having her try and reach her potential.”   
Furthermore, parents whose children did not receive a definitive diagnosis from TES expressed 
frustration with the continuing uncertainty largely because they want to know how best to help 
their child, as one parent in the uncertain category said:  “I just want to know what it is so we can 
deal with it.  And you learn about it, figure it out, help her the best we can, it’ll be better to help 
her.”  Another parent whose child received a negative result similarly related: 
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“I just would love an answer.  It doesn’t seem like you get them.  I have to, you know, be 
ok with that.  I get ok with it and then when she doesn’t feel good, I’m not ok with it.  But 
I don’t know, there are so many emotions with all of this.  I do wish, I just wish I knew 
like exactly the right way to help her and what to do and what not to do. When to push 
and when not to push with her.  But, I don’t know, I just do the best that we can. With the 
information we have.”   
This mother also voiced a common fear of the unexpected that accompanies living with an 
uncertain diagnosis, saying, “Still like uncertainty that something could be wrong and we just 
don’t know it yet.  …  I usually handle it pretty well but every couple of months I cry about it and 
then I get on with life.” Interestingly, this parent concluded her daughter was the source of 
uncertainty, not the test: “I was hoping to get an answer, but that’s nothing the testing does, 
that’s just [my daughter], like there’s just nothing good to find out I guess. As of right now.”  
Another parent similarly absolved any limitations of the test by blaming bad luck:  “we didn’t get 
more of a clear cut answer that we were looking for, hoping for but, I mean, that’s nothing 
against the test.  That’s just our luck.” 
The ambiguity and complexity of exome results left openings for parents to find meaning 
in the uncertainty.  Participants in the negative and uncertain categories, while frustrated by the 
lack a diagnosis, often interpreted non-answers as evidence their child does not have any of the 
more severe conditions listed on their doctors’ differential diagnoses.  They, therefore, found 
significant meaning in their child’s TES result even though it did not provide a causative answer.  
For example, one parent whose child received an uncertain result said: “In a way we were really 
looking forward to finding out something, but then on the other hand, when there are so many 
things out there, and some of the things that they were pointing us in the direction of I was really 
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relieved we didn’t have.”  Similarly, following a negative TES result, another parent said: “And 
what’s unfortunate is that it hasn’t led us to anything. It’s ruled out a lot but it’s not confirmed 
anything.  At least we know what he doesn’t have, which is a good thing.”  Participants whose 
children did not receive a definitive diagnosis from TES perhaps searched for meaning as a way 
to cope with the uncertainty.  As one mother vividly described the struggle to resolve 
uncertainty: “…the entire process whether it is the full exome sequencing or just a regular 
genetic test it is extremely emotional draining -the unknown, you can’t control it and the waiting 
time. …  At a point, I can tell it is like you are playing a game and at a point you just want to 
give up, but you have to put your shoes on and keep going.” 
Furthermore, since TES only reports back variants in genes that could explain at least 
some of the patient’s symptoms, searching for meaning in uncertain or negative results can lead 
to confusion and false hope.  For instance, one parent whose child received VUS results in genes 
that were not thought to explain his condition (meaning, she was in the negative category) 
seemed convinced that the test proved her child was different because of genetics, which brought 
her comfort.  Moreover, she seemed to interpret ‘variant’ as meaning a variant of the condition 
rather than a genetic variant. 
“I think it definitely helps you explain your child better even if it’s not a definitive but you 
can still say there are these things genetically wrong with my child and even though they 
don’t know exactly definitively this is the syndrome he has or whatever that I can say with 
certainty because of this test that he has these variants in his DNA.  … You can’t say yes, 
this is exactly what it is but it still gives you that idea because he does technically have 
these things but they’re not 100%.   It may be 30% of this and 50% of this and you know 
what I mean.  So like I said, that’s just what makes my kid so unique and amazing.”    
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“It helps me to, you know… I think even with family and friends, they just always looked 
at [my son] as this bad, hyper kid when he’s not bad at all.  Yes, he used to be hyper.  
Yes, he’s a little different than other children.  But I can tell you because we did this 
certain test, even though it’s not definitive, that this is why my son is the way he is.  So I 
think it just helps me explain him better to people and not get angry for people not 
understanding or make me upset when people make comments because they just…they 
can’t judge him based on what they see on the outside.   They need to realize that 
genetically, that’s why [my son] is the way he is.  So I think it almost gave me some fuel, 
you know, like, it really did.  It gave me something to just kind of defend [my son] in a 
way.  I mean, definitely.  Even though it’s not definitive.” 
Another parent whose child did receive a pathogenic variant from TES, also interpreted 
the other VUSs as meaningful, believing them to indicate that certain conditions were being 
passed on in the family even though these conditions did not match her daughter’s presentation. 
“Well we passed on a lot of muscular skeletal disease in our family.  But there’s no real 
evidence of it. She has kyphosis and scoliosis, so there’s probably, it’s certainly not a 
surprise if you look at the number of muscular skeletal variants that she has, what 
variants could be a combination of certain things that she ends up having that more 
dramatically.  It could not be related at all, who knows? But interesting that it’s coming 
through the family and yet nobody’s had Duchene’s muscular dystrophy, I mean not that 
that’s one of them, but there’s really, really strange rare conditions.”   
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5.2.3 Valuing the Intangible 
Participants in all categories described intangible yet profoundly meaningful benefits to TES.  In 
addition to clinical utility for some, TES has the potential to provide personal utility to many 
more families.  Subthemes include relief, validation, inspiring altruism, hope for the future, and 
obtaining support. 
5.2.3.1 Relief 
Relief was a major sub-theme expressed by the participants consistently across the three different 
groups.  Relief took on many forms including peace of mind, reducing anxiety and stress, 
clarifying risks to other relatives, and absolving blame and guilt.  Importantly, relief not only 
ameliorated one’s own psychological distress but also led to positive impacts on family 
relationships by helping to ease marital stress and opening up a dialogue with their children and 
other relatives, as described further below. 
Without a diagnosis, many parents automatically think they are somehow to blame for 
their child’s condition and must find a way to cope with that thought, as exemplified by one 
parent who shared:  
“My husband and I were grasping at straws.  Was it because I drank too much chocolate 
milk and I found out later that chocolate milk … had caffeine in it.  I also was on a 
gallbladder diet and ate tuna fish all the time and I thought was it the mercury.  Was it 
the vaccinations? Um, I had a fall when I was pregnant and had physical therapy and 
they put some heat on my back.  Just, you know, we just were searching, you know, for 
answers and causes.  But finally we came to a peace that,  … we’re probably never going 
to find out.”    (Positive) 
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When TES was offered after years had passed since they stopped searching for answers,   this 
peace was momentarily disturbed by bringing questions of cause back to the surface: “I guess 
that it just brought to mind the whole questioning again and we had kind of accepted everything 
and not thought about the why of her condition so it just brought that to mind.”  Yet upon 
receiving an answer from TES, this parent expressed relief as they were absolved of their 
perceived guilt: 
“When we found out the cause of her, after the exome sequencing, we found out the cause 
of her disability, I thought I had accepted everything but I just started to cry. It was 
finally an answer to, you know, what had happened.  I think that I had accepted that I 
wouldn’t get an answer but it was a gift that I did get an answer.” 
Moreover, feelings of guilt and blame for causing their child’s condition had contributed to 
increased marital stress.  Receiving an answer from TES helped relieve this stress in this 
relationship: 
“It has kind of given us a peace of mind and I think it has taken that stress, you know, this 
whole disability that she has has been very stressful on our marriage.  We, you know, 
we’re doing fine now but we were told that 85% of parents that have special needs 
children end up getting divorced and um, we never considered getting divorced but it 
definitely put a strain on our relationship because of all the caretaking responsibilities.  
So I think this diagnosis since we’ve know, it’s just given a little bit more peace about it 
and we’re able to, you know, that aspect is just one less stressor in the relationship.  It 
took a little bit of that away.” 
Even those with uncertain results found comfort in finding a potential genetic cause for their 
child’s condition.  As one parent related: 
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“Did I eat something wrong? I was working full time – should I not have worked?  
Should I have rested more? Should I have drank more?  Yeah, yeah, you have no idea the 
things… oh that one time that I kind of slipped and fell – did I twist wrong?  One time, 
you know, [my husband] knocked me in the stomach because he rolled over too fast in 
bed.  You know, it’s everything under the sun that goes through your head that you did 
something.  So that was really huge for us.  Or at least for me. That alone was well worth 
taking the time and the test.   That’s a whole huge peace of mind.  That’s a whole load.   
Which gives you more time to focus on things you should be focused on, than worrying 
about something that doesn’t matter anyway because you can’t change it anyhow.”  
Upon receiving a potential genetic cause for their child’s condition, some parents shifted 
the narrative from one of self-blame and guilt to one of Divine purpose.  Parents who interpreted 
their child’s TES results as providing some kind of answer, also concluded that their child was 
made this way by G-d for a purpose and a reason.   Parents found strength in this realization and 
were less anxious about their child’s future: 
“But it just confirmed that, this was, you know, was meant to be and that she was 
designed that way.”  (Positive) 
 
“We know we didn’t cause it and even though we don’t know what’s to come, I think it’s 
just made it easier to just accept that she is who she is because G-d wanted her to be this 
way and for us that’s enough to say ‘ok, we give up’ [laughter] .  Now this is what she’s 
meant to be.  G-d gave her to us specifically.  He chose us to raiser her, so we’re going to 
do the best we can and I think that has really impacted both of our lives with more an 
urgent responsibility to do our best for her.  And to kind of get that divine intervention 
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thing going where you feel, ok she’s here for a reason and He gave her to us for a 
reason.  And that’s even helped with my younger daughter to be able to say, look G-d 
made her this way for a reason, and He put you here in your situation for a reason.  So 
it’s definitely alleviated some stress and opened up a dialogue and, you know, maybe 
impacted all of us in, I think, a positive way.” (Uncertain) 
 Another source of relief identified in this study was that TES results helped clarify risks 
to other family members.  All participants in this study who received results with pathogenic 
variants had de novo mutations. Therefore, the test result alleviated the fear of another child in 
the family being born with the same condition in the future: 
“The main thing was having the knowledge that my daughter, my other daughter 
wouldn’t have to worry about what she might be passing along to children that she would 
want to bear in her life . So the fact that I could spare her, that was probably the best 
outcome.”  
5.2.3.2 Validation 
Without a diagnosis, parents often had lingering concerns that they were being hypochondriacs, 
that they were bad parents, or that others were judging them as bad parents because of their 
child’s condition.  Participants who received a diagnosis from TES cited that having their 
concerns and struggles validated was an important outcome of testing:   
“I think that that’s more validating that there something really definitive, that there’s a 
reason why she is built, that there is a reason why she looks the way she does.  Just her 
genetics.”   
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“I have to tell you quite frankly, I am happy with the results, not that I have an option to 
be happy.  I am quite satisfied with them because it just really affirms every concern I 
have shared with the doctors at each of the clinics.” 
 
“It felt like we were validated.  Like our struggles had been validated.  …  I kind of felt 
validated you know, that I was able to tell like close family members, past teachers and 
friends that there really was something unique about her.” 
The positive impact of having a child with special needs was well reported among this group of 
participants.  Siblings in particular were noted to develop a strong sense of compassion and 
universal inclusion.  Families were also noted to have gained strength through adversity.  Parents 
did, however, also note the difficulties of growing up with a sibling with special needs who is 
given more attention and treated differently.  Participants were able to use TES results to discuss 
the differences between their children in order to validate the struggles they endured and to 
alleviate feelings of worry and resentment: 
“And that’s even helped with my younger daughter to be able to say, look G-d made her 
this way for a reason, and He put you here in your situation for a reason.  So it’s 
definitely alleviated some stress and opened up a dialogue and, you know, maybe 
impacted all of us in, I think, a positive way.”  (Uncertain) 
 
 “… the older daughter did have to sacrifice a lot and I’m sure she thinks that, when she 
was younger, [my affected daughter] got a lot more attention that she did, which she did.  
But it wasn’t our choice. So I think that her knowing that there was a definite cause for 
this may help her accept all the requirements of her special needs a little bit easier.  I 
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don’t want to say anything negative about my older daughter.   She’s just wonderful and 
she’s now a Special Ed teacher and she’s just so compassionate.  I think that this whole 
process of having [a daughter] with special needs has only made our family stronger and 
has only made our family better. So you know I don’t want to say anything negative about 
her but I do think that having the diagnosis probably helps her understand that you know, 
that everything was justified.” (Positive) 
5.2.3.3 Altruism 
Parents in all groups also expressed motivations of altruism before and after TES testing.  Those 
who received a diagnosis felt inspired to participate in research to further advance knowledge 
about the condition and to join support groups in order to serve as mentors to others who may be 
diagnosed currently or in the future.  As one participant expressed: 
“I connected with some other parents that have a child with the same genetic disorder 
and we set up a Facebook support page and that’s been a positive since most of their kids 
are age 5 and under, I can be a support to them and they ask me questions and I can feel 
like I can be a mentor so that’s been a positive outcome of knowing.”  
Additionally, those who received uncertain results were still encouraged by the idea that just 
getting their child’s genetic information into databases will help advance the field and may lead 
to answers for others, if not for themselves.  As one parent stated: 
“Knowing that I’m not only doing something for myself and my child but that it’s 
potentially helping another parent find out something about their child in the process  – 
that was the biggest reason we decided to do it because it’s not just for us but it’s for 
parents that might not have any answers about their kids.  There’s not much that we can 
do but one blood draw and that’s it, you know, and her map is in the system  and my 
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husband’s all about the maps.  [Laughter].  You know the more information that is 
available, the further we can advance.” 
Even those without an answer found positives in the option to enter into the research phase 
because of the potential to help others in the future.  For instance, one parent shared: 
“I also like that they said that if this doesn’t help, all this testing can further… like they 
were going to put us in this study group too, that they could further help other people 
even if it wasn’t helping [our daughter] directly, we weren’t getting answers directly, it 
would help out with the research.” 
One parent who described a particularly frustrating and lengthy fight to get insurance approval 
after multiple rejection letters discussed a strong desire to use her experience to help other 
families through the process: 
“I think that for us if there is something we can do to advocate for another family, to 
write letters to insurance panels.  Whatever we can do I think for us is what we want to 
do.  We have our answers.  We have our plan, but there are so many other families that 
are in the boat now that we were in three years ago and that are just waiting.  I think for 
us it would be just if there is something else we can do just to make it easier for 
somebody else.  Make it fast or more accessible.  That’s the big thing for us.” 
5.2.3.4 Hope for future 
Parents in all categories also had a well-developed hope for the future following TES testing.  
Some who did not receive answers were amazed by the advances in technology that made TES a 
possibility and looked forward to future advances that may lead to an answer for their family.  
Others who had a diagnosis hoped that this answer would lead to increased knowledge about the 
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condition and better treatment or management strategies.  This was exemplified in the following 
statements: 
“And who knows, maybe they’ll end up identifying some sort of drug down the line that 
plugs in that broken X and things change.”    
 
“The negative is there’s just so much unknown still.  You know, in [my son]’s case, he 
has these variances but we don’t know what they mean.  And that’s just…that’ll come I 
think as technology advances and new discoveries are made in science.  It’s 
disappointing but it is what it is [laughter].  That we’ve come this far is pretty cool 
though.” 
5.2.3.5 Obtaining support 
The importance of finding support groups has been well documented in the literature.  Similarly, 
participants in this study spoke about the positive impact of sharing ideas and connecting with 
parents going through similar experiences has had on their lives.  As one parent voiced, finding a 
support group “has been life-changing” … to be able to “network and find answers to questions 
you may be having.  Then to be able to talk to a mom who gets you, who understands your 
frustration and your stress.  You know because our lives as a disabled parent is not like a normal 
parent.  ‘cause you know, their biggest issues to us – we would love to have that as our biggest 
issue.”   Support doesn’t have to be disease or condition specific as this participant continues to 
relate: “Even just the fact that they have a disability – sometimes that’s just all it takes.  Just to 
get the understanding where you can say ugh, I had 6 doctor’s appointments this month, you 
know, and have somebody understand what that means.  Or you know, we did this test or we did 
that test, you know, just somebody who gets it, is nice.”   
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As one parent described, however, for those parents who received a diagnosis, seeking 
support from other parents whose kids have the same condition provides the opportunity to share 
information about therapies or strategies that have worked, insight into what to expect at 
different developmental stages, and the knowledge that they are not alone:  
“So that was the good thing too with the social media that got us hooked up with these 
families.  To see what works and what isn't working for them.  What is available in 
different parts of the world. … I think it has bridged us to a lot of other people with the 
same diagnosis.  …  When we started connecting with those folks it just didn't feel so bad.  
We kind of had the overwhelming bad feeling at first and then once we started connecting 
with these folks it didn't seem so bad.  …  We can kind of relate.  We have some friends 
with little ones, but not many.  I think it's just opened us up to more people.”  
While physicians can serve as a source for some of this information, when coming from those 
who are living it daily it is much more comforting and meaningful, as exemplified by one 
participant: 
“And just thinking and feeling – you know, we knew that it was rare – but thinking that 
we were… feeling like we were the only ones dealing with these particular issues is very, 
very lonely and to not have anybody but each other to bounce ideas off of. … Because of 
them we get more information about the condition and we can talk to other parents who 
are dealing with the exact same stuff that we’re going through.  It’s just so helpful to 
have that kind of peer support. … It’s coming from the people who are affected, it’s not 
coming from a physician’s office who says well this is how you should be feeling or this is 
what we expect that you … this is the parents that have gone through this and they’ve 
made into a, literally, worldwide organization of support and it’s fantastic.” 
 50 
6.0  DISCUSSION 
This exploratory qualitative study was conducted in order to understand the attitudes, perceptions 
and beliefs of parents towards targeted exome sequencing of their chronically ill children.  
Through thematic analysis of transcribed semi-structured interviews, a number of central themes 
emerged related to managing expectations, living with uncertainty and valuing the intangible.  
By developing a deeper understanding of the complexities and nuances of the parental 
experience with TES, alternative strategies for counseling this population of patients may be 
considered. 
6.1 DISCUSSION OF THEMES 
6.1.1 Managing Expectations 
According to the Orphan Product Act of 1983, a rare condition is defined in the United States as 
one that affects less than 200,000 people in the US42. Among populations in the US and Europe, 
there are approximately 5000-8000 conditions that can be defined as rare. Likewise, there are 
6800 conditions on the National Institutes of Health’s list of rare diseases43. Over 30 million 
individuals in the US are thought to currently be diagnosed with a rare condition42,43.  Genetic 
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conditions make up approximately 80% of rare conditions, which also includes infections, toxic 
exposures, and nutritional deficiencies.  
Parents of children with chronic conditions often express simultaneous feelings of joy 
and sorrow, hope and hopelessness, and defiance and despair44.  The demands of caring for a 
child with a chronic condition can be overwhelming and contribute to feelings of depression, 
anxiety, uncertainty over child's future, and restrictions on social life45.  While parents of 
children with rare diseases face issues related generally to caring for a child with chronic health 
needs they must also cope with issues related to lack of diagnosis, limited availability of support 
and limited knowledge among healthcare providers.  The prolonged search for a diagnosis can 
substantially impact parents’ hopes and expectations for their child and for genetic testing.  
Understanding how these hopes and expectations evolve can help tailor counseling strategies in 
the setting of targeted exome sequencing. 
Hopes and expectations are related but independent constructs46.  A recent integrative 
literature review was conducted to devise a conceptual model of how hopes and expectations 
each develop and then either diverge or converge47.  This model described hopes as determined 
by preferences and expectations as determined by probabilities.  The perceived likelihood of an 
event is influenced by past experiences and current knowledge as well as optimistic bias, or the 
tendency to overestimate the likelihood of positive outcomes and underestimate that of negative 
ones.  Because hopes and expectations are derived from distinct constructs, both can be held 
concurrently even when they are divergent47.  Taking this concept into practice, a study found 
that while health professionals view a tension between parental hope and medical prognosis, 
parents did not see these two states in competition with each other.  Health professionals feared 
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that seemingly unrealistic hope meant parents are not fully informed while parents placed value 
on hope in helping to cope with illness48. 
Similarly, in this current study, parents’ hopes and expectations often diverged without 
creating tension. Additionally, while parents all had similar hopes of finding answers for their 
children, their expectations diverged from one another based on their individual past experiences 
and personally held optimistic biases.  For instance, parents cited multiple rounds of negative 
genetic tests in the past as informing their expectation of more of the same from TES.  However, 
other parents with an optimistic view of technology expected answers from this scientifically 
advanced test.  Interestingly, parental satisfaction with TES among these participants did not 
depend on whether either their hopes or expectations for results were met.  Rather, anticipatory 
guidance of the test’s limitations along with the knowledge that they’ve pursued every avenue 
open to them at this point seemed to be the most significant components of parental satisfaction 
with TES.   
Furthermore, while all parents expected up to a six month wait for results, their 
experiences during this wait period diverged as well.  Some parents were able to put the test out 
of their minds after circling the six month mark on their calendar expressing surprise it passed so 
quickly, while others waited furtively for what seemed like an interminable length of time.  
Those participants who were not troubled by the wait time tended to have older children whose 
condition reached somewhat of an equilibrium that did not suggest a shortened life expectancy.  
These parents also acknowledged the futility of agonizing over issues out of their control.  On 
the other hand, those that were more anxious tended to have younger children where the question 
of life expectancy was more uncertain.  Further studies exploring the factors determining how 
parents experience the wait for TES results as well as strategies parents employed to reduce 
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anxiety during this time could help illuminate ways clinicians may help parents manage the long 
wait.  
6.1.1.1 Uncertainty in chronic illness 
Mishel first developed the theory of uncertainty in illness defining uncertainty as “the inability to 
determine the meaning of illness-related events, occurring when the decision maker is unable to 
assign definite value to objects or events, or is unable to predict outcomes accurately49.”  Illness 
uncertainty has been described as falling into four broad categories: ambiguity regarding the 
state of the illness, complexity of medical care, lack of information, and disease 
unpredictability50.  Mishel’s theory was later re-conceptualized to incorporate the temporality of 
chronic illness where uncertainty is continually reevaluated as the relationship with illness 
continually evolves51,52.    
Mishel’s theory of uncertainty in chronic illness is composed of three main components: 
Antecedents, Appraisal, and Outcomes.  Antecedents are any factors that form the foundation for 
the individual’s worldview, which may include medical, psychological and social factors.  
Appraisal refers to the individual’s assessment of uncertainty as a danger or an opportunity based 
on the incorporation of their antecedents.  Finally, viewing uncertainty as a danger or an 
opportunity will determine whether the outcome is psychological distress, coping, or 
maintenance of the status quo50,51.  Individuals who perceive uncertainty to be a danger tend to 
attempt to bring clarity by seeking information53.  Alternatively, when uncertainty is viewed as 
an opportunity, individuals prefer to maintain uncertainty rather than learn troubling information.  
Therefore, these individuals tend to avoid information53. Interestingly, while all participants in 
this study initially proceeded with TES seeking information, some who remained with 
uncertainty ultimately recognized opportunity in the lack of information. These individuals found 
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solace in not receiving a diagnosis that was life limiting or with a deteriorating prognosis and did 
not have to face limiting their child’s potential to the box created by a definitive diagnosis.  The 
impetus to retrospectively interpret uncertainty as opportunity may have different psychological 
origins when uncertainty is the only option rather than when it is a preconceived choice.  Parents 
who hoped for clarity may cope with continued uncertainty by searching for its benefits.   
However, given the choice, these parents still want answers.    
Whitmarsh highlighted an additional view of uncertainty as opportunity when specifically 
addressing individuals diagnosed with genetic conditions54.  Because genes are described as 
unchangeable determinants of human biology, genetic diagnoses are often expected to be definite 
with a specific, inescapable trajectory.  Introducing uncertainty in the severity or prognosis of a 
genetic condition can free individuals from being defined by a narrow label and allow hope for 
the potential to exceed the narrow limitations of their diagnoses54. 
In the midst of chronic uncertainty regarding a child’s condition, parents’ desire for a 
diagnosis may change in intensity and be motivated by different needs over time.  A number of 
studies have described different issues that parents of children with unexplained chronic 
conditions may consider in their need for a diagnosis: acquiring a label, validation, determining 
etiology, clarifying a prognosis, obtaining proper treatment, reaching acceptance, and seeking 
social support55–57.  Determining an etiology was cited as important for absolving blame and 
clarifying recurrence risks55,57.  Parents’ complex attitudes toward uncertainty run through each 
of these dimensions, preferring to maintain uncertainty in some situations while seeking clarity 
in others and sometimes desiring both simultaneously.  For instance, while some want a label in 
order to give a name to their child’s condition and to obtain appropriate services, they also fear 
limiting their child’s potential by establishing the boundaries of a definite diagnosis55.  Similarly, 
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many parents want a clearer prognosis so they can plan and anticipate for the future yet there is 
also the fear of possibly confronting a shortened life expectancy55.  Furthermore, in the absence 
of a definitive diagnosis, parents had greater difficulty reaching acceptance of their child’s 
condition and also struggled with issues of self-blame for causing their child’s condition55.  In 
one study, validation was cited as the most common reason parents sought a diagnosis57.  A 
genetic diagnosis would validate that there is a real problem with their child and that the parents 
are not to blame, relieving a major source of psychological stress. 
By the time they were offered TES, some parents in this study had reached a point of 
acceptance concerning their child’s condition.  While some expressed lingering thoughts of self-
blame and worries about life expectancy, other parents discussed eventually becoming 
accustomed to their new normal.  Those parents whose children received an answer through TES 
expressed feelings of relief, possibly not acknowledging the remaining stress caused by guilt 
and/or concern over an uncertain life span until that stress was removed.  Those that did not get 
an answer, while frustrated that their diagnostic odyssey continues, also felt a sense of relief in 
knowing they have done everything they can for their child by pursing TES.  These parents have 
become accustomed not only to their child’s condition but also to not finding answers in genetic 
testing.  While previous studies reported multiple factors driving parents’ needs for a diagnosis 
for their child, parents in this study were primarily driven by a need to clarify life expectancy and 
a desire for information that will best help their child either obtain resources or find appropriate 
treatment.  Although parents in the positive category remarked on the relief felt upon realizing 
they were not to blame for their child’s condition, participants declared that they are not 
interested in knowing why their child is affected but rather how they can give him or her the best 
life possible.  Similarly, parents who received an answer were happy to have it yet said they are 
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not interested in labels unless they can be used to obtain services, resources, treatments, or 
therapies that are otherwise unavailable. 
6.1.1.2 Uncertainty in genetic testing 
The need for interpretation of results in genetic testing can add another layer of uncertainty in the 
results themselves.  Like typical lab tests, genetic tests can produce either positive or negative 
results, either confirming or ruling out the condition tested.  However, unlike most typical lab 
tests, genetic tests can also produce an indeterminate result termed “variant of uncertain 
significance” (VUS).  A VUS cannot officially be declared pathogenic or benign due to 
inadequate data, leaving parents with a result that is not an answer.  Similar to WES, 
chromosomal microarray (CMA) is an unbiased approach to interrogating large sections of the 
genome simultaneously and can uncover rare, complex genetic anomalies that are not detectable 
by traditional genetic testing and also often results in VUSs.  Parental perceptions, understanding 
and adaption to uncertain results following clinical CMA testing has been reported58–60 but 
similar studies in the setting of WES results have not been found.   
Studies exploring the parental interpretation of VUS results from CMA revealed a 
conflict between the interpretation of a VUS providing a cause but not a meaning for their child’s 
condition58,59.  Many parents interpret this genetic difference as proof that their child’s condition 
is genetic, which they can use to alleviate guilt, fight for services, and hope for better 
information as more data is accumulated in the future.  Again, even in the context of a VUS, 
parents described the result as delivering relief, providing validation, and helping reach 
acceptance59.  However, VUSs still leave parents unsure about the health implications for their 
child60.   The importance of support groups and connecting with other parents was further 
highlighted in the context of rare diagnoses that lack information being described as 
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“isolating59.”  Moreover, due to the rarity and novelty of many CMA results returned to patients, 
parents are often faced with uncertainty regardless of whether the genetic diagnosis is definite or 
uncertain, which engenders both frustration and hope61. 
The current study reveals a number of parallels between the impact of uncertainty in 
CMA and TES.  Similar to prior studies, participants in this research viewed VUSs as proof that 
their child is genetically different even if the genetic differences uncovered by the test are not 
themselves the definite cause of their child’s condition.  Having evidence that there are 
differences in their child’s genes gives parents reassurance that the answer lies somewhere in 
their child’s genetic makeup but technology is not advanced enough yet to detect it.  Based on 
this interpretation of VUSs, parents without answers still expressed feelings of relief, absolution 
of guilt and validation, used the information to defend their child, and had hope for better 
answers in the future.   It is unclear if these misinterpretations or over-interpretations of the 
meaning of VUSs is due to a lack of understanding or is an attempt to cope with the reality of 
caring for a child with an undiagnosed chronic illness.  It is important to understand the impetus 
for this response because each would require a different counseling strategy.  If parents do not 
understand that genetic variability exists among all individuals or how to distinguish between 
variants of uncertain significance and pathogenic variants, then more in depth education on these 
topics during or prior to results disclosure is necessary.  However, if parents are using VUSs like 
a life raft in a sea of uncertainty, then alternative strategies to seek relief from stress, absolution 
of guilt, and to maintain hope might be explored. 
Similar to CMA, TES interrogates large, previously unchartered genomic territory and 
even results that provide certain diagnoses are not always able to provide certain prognoses.  The 
children of participants in this study that did receive positive results from TES were all 
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diagnosed with rare conditions.  As prior studies found subsequent to diagnoses with rare copy 
number variants, parents in this study expressed dichotomous reactions of both gratitude and 
frustration.  While grateful for an end to the diagnostic odyssey, parents were also frustrated by 
the lack of clarity in the meaning of their child’s result.  The ability to participate in research 
related to their child’s condition or the opportunity to serve as mentors to other parents of 
children with the same rare diagnosis may be avenues to channel some of their frustrations. 
6.1.2 Valuing the Intangible 
While the diagnosis or presentation of a chronic condition can initially spark feelings of shock, 
grief, loss, anger, and guilt, many parents are able to adapt over time62.  Adaptation can occur 
through meeting the social, informational, and emotional needs of parents of children with rare, 
chronic conditions63.  Participants in this study disclosed a number of adaptations used to cope 
with their child’s chronic condition, highlighting the potential for personal utility of TES.  
Adaptations included participation in support organizations and research, acquiring knowledge, 
maintaining hope for the future, and reframing their world views.  In other studies, parents of 
children with chronic conditions have been shown to display positive adaptation through altering 
their perceptions and prior beliefs by focusing on their child's strengths, on the positive impact 
their children have on those around them and on their hope for the future, finding meaning, 
creating new dreams, and framing their situation as a 'new normal’62,64. By actively altering their 
world view, parents are able to regain a sense of control62.   
Social needs of parents of children with rare, chronic conditions include access to support 
groups, support of family and friends, and the ability to communicate with parents in similar 
circumstances. When these social needs are not met, parents display feelings of isolation and 
 59 
loneliness63.  Likewise, study participants spoke about the life changing importance of peer 
support and support groups.  Support groups did not need to be disease or condition specific to 
be beneficial.  Even in the absence of a definitive diagnosis, therefore, referral to a group of 
parents that can understand the daily life of a parent of a child with special needs is critical.  
Informational needs refer to a parental desire to be personally informed as well as 
frustration over lack of knowledge of rare diseases among healthcare providers. Because it is 
often difficult for healthcare providers to be knowledgeable about every rare disease, the parents 
may become the experts and many parents must gain knowledge through doing their own 
research, going to conferences, searching the internet and talking to others with the same 
condition63.  Similarly, participants in this study wanted to know disease course, life expectancy, 
and availability of services, treatments and management so they can plan for the future and so 
they can provide the best life possible for their child today.  TES results disclosures address these 
topics and should include information that can be easily shared with other healthcare providers 
who may not be familiar with rare conditions. 
Emotional needs vary with the level of disease severity, needs, and caregiving 
responsibility. While the initial diagnosis can induce feelings of shock, even with the passage of 
time, parents face chronic stress, guilt, frustration, anxiety, uncertainty, and fear. Receiving a 
diagnosis is important in providing some relief of these emotional stressors63.  For many couples, 
the stress of raising children with chronic conditions negatively impacts their relationships65. 
Others, though, have been shown to benefit from parenting a child with special needs by 
strengthening their bond and becoming more unified as a family66. Siblings and parents have 
benefited through the development of a positive world view to include greater acceptance, 
tolerance, and patience. Through participation in support groups and advocacy, parents and 
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siblings also develop new, meaningful relationships and become part of communities they would 
not have experienced otherwise65,66.  Likewise, parents in this study spoke of the stress caring for 
a child with special needs has had on relationships with their spouses and the struggles endured 
by their other children.  However, families have also discovered strength in overcoming 
adversity and siblings tended to develop warmth, compassion and patience beyond their years.  
TES aided in adaptation to living with a child with a chronic condition by providing validation 
for their struggles and removing thoughts of blame.  Having a reason or even the suggestion of a 
reason contributed to reduced parental stress and opened up a discussion with their other children 
concerning the seeming disparities in attention given to them compared to their affected siblings. 
The personal utility found in meeting their social, information and emotional needs is 
also commonly cited in the literature as a benefit of receiving genetic testing results2,5,7,8,35,38,61.  
Genetic testing has resulted in relief61, reduced uncertainty and anxiety61, improved ability to 
prepare for the future35, reinforcement of compliance with recommendations38, increased 
awareness of health risks38, and empowerment and control5.  Additionally knowledge is viewed 
as being intrinsically valuable and parents have described a sense of personal responsibility to 
know all they can about their child61,67.  For parents who feel this responsibility, any knowledge 
– even uninterpretable knowledge – is inherently valuable61. 
6.2 STUDY LIMITATIONS AND FUTURE DIRECTIONS 
This study had several limitations.  The sample size was small and limited to one genetics center 
where all participants were seen by the same genetic counselor for post-TES counseling.  
Results, therefore, may not be generalizable.  Small sample size also limited ability to compare 
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experiences among groups.  Additionally, all participants were Caucasian females and most had 
at least some post-secondary education, limiting the diversity of the study population.  Views 
that appeared common may reflect culture-specific norms and a richer description of the parental 
experience could be gained by similar studies with a more diverse population.  Participation in 
this study was voluntary and results could be a reflection of selection bias whereby those 
agreeing to participate in research may have a particular perspective that is not necessarily 
representative of the general population.  The index patients in this study had diagnoses that 
ranged in etiology and severity.  Parental perceptions may vary as a result of specific diagnosis. 
This was a retrospective study. Stated expectations, therefore, were likely influenced by outcome 
and dependent upon the participants’ recollection.  Future longitudinal studies encompassing pre-
and post-test data collection may provide a more accurate reflection of parents’ thoughts, 
expectations, and perceptions in real time.  Since the experience of parents whose children 
underwent TES testing has not been previously reported in the literature, this study intended to 
investigate the full experience of parents throughout this process. Therefore, the questions 
covered a broad number of topics and did not dig deeply into any one topic.  Further research 
could focus more deeply on a specific aspect of testing.  One such aspect that may benefit from 
additional investigation is how, when, and how much information on basic genetics and exome 
sequencing should be introduced to the parents.  In this study of 11 parents, some were 
overwhelmed by receiving too much information in one sitting while others expressed 
fascination and appreciation for detail.  Still others balked at the complexity of exome, 
concluding that no amount of information would bring parents to a full understanding of the test.  
A larger, more focused survey of parents whose children have undergone TES could help 
determine their preferences, needs and expectations for receiving this information.  Based on 
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these results, alternative strategies could be developed for educating parents such as through the 
development of brochures or providing links to appropriate online resources.  
6.3 CONCLUSIONS 
This is one of the first studies to explore the parental experience with clinical targeted exome 
sequencing in a genetic counseling setting. The results describe the complexities and nuances of 
parents’ attitudes and perceptions throughout the TES testing process.  Satisfaction with TES 
was not dependent upon outcome but rather is a function of managed expectations.  Awareness 
of the test’s limitations, an accurate appraisal of the wait time, and a feeling that TES is the most 
comprehensive test currently available all contributed to parental satisfaction regardless of 
whether their child had a positive, uncertain or likely negative result.  Furthermore, parents in all 
categories faced continued uncertainty in the face of their child’s TES results resulting in 
feelings of both relief and frustration.  For those who received an answer, there was relief in 
finally having a diagnosis yet frustration when that diagnosis was so rare it came with limited 
information.  For those who did not receive an answer, the lack of a more serious and life 
threatening finding brought relief, yet parents were still frustrated by the unending diagnostic 
odyssey.  Finally, in addition to feelings of relief, parents in all categories were able to find 
personal utility in undergoing the TES process such as validation of their concerns and struggles, 
the opportunity to participate in research, finding peer support and maintaining hope for the 
future.  Developing a deeper understanding of parents’ motivations, attitudes, and perceptions 
regarding the TES process has significant public health implications in that it may allow genetic 
counselors and other health professionals to find alternative strategies for counseling this 
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population of patients.  Future research should focus on determining the generalizability of these 
results with larger, more diverse cohorts, on elucidating how these perceptions and attitudes 
evolve temporally through longitudinal studies, and on assessing the adequacy of counseling 
strategies aimed at addressing the nuances of the parental experience with pediatric TES.  
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7.0  PUBLIC HEALTH SIGNIFICANCE 
In this study, parents expressed a desire for information on the basics of genetics and exome 
sequencing prior to receiving their child’s result.  Currently, parents receive most of this 
information during the results disclosure visit and some participants in this study were 
overwhelmed by the amount of information received at once.  In order to reduce parents’ stress 
and better prepare them for the results disclosure visit, the following is a proposed method for 
the development of educational materials for those undergoing exome sequencing.  These 
materials could be sent to parents to study prior to the results disclosure visit without creating a 
strain on resources by requiring an additional clinic visit.  This proposal includes a needs 
assessment, a method of material development and an evaluation of efficacy and parent 
satisfaction. 
7.1 BACKGROUND 
In the United States, a rare condition is defined as one that affects less than 200,000 people in the 
US42. According to the Genetic and Rare Diseases Information Center of the National Institutes 
of Health, there are 6800 conditions rare conditions known43 affecting 25-30 million individuals 
in the US42,43.  Genetic conditions make up ~80% of rare conditions, which also includes 
infections, toxic exposures, and nutritional deficiencies. Almost half of all patients with 
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unknown suspected genetic disorders receive a genetic diagnosis through traditional genetic 
approaches12.  Traditional clinical genetics refers to a comprehensive physical evaluation, 
chromosomal studies, biochemical studies, single gene testing, gene panel testing, or microarray 
analysis.  Of those patients who did receive a genetic diagnosis through traditional genetic 
approaches, 72% were diagnosed during the first diagnostic evaluation12.  Those without a 
diagnosis following their initial evaluation embark on a ‘diagnostic odyssey’ that can include 
multiple rounds of genetic testing, consultations with various specialists, radiological 
assessments (CT scans, MRIs, skeletal surveys), cardiology assessments (Echo, EKG), and 
neurological exams (EEG, sleep study) in an attempt to obtain a clinical diagnosis.  This 
diagnostic odyssey can become emotionally and financially draining.  WES or whole genome 
sequencing (WGS) as a second-line test might increase yield and decrease time to diagnosis 
thereby decreasing costs of subsequent testing.   
7.1.1 Cost effectiveness of whole exome sequencing 
Exome sequencing is a relatively new genetic test offered clinically since 2012. Some 
preliminary reports analyzing the cost effectiveness of WES are available, however, more 
comprehensive analyses are still needed.  Recently, an economic analysis of WES/TES at CHP 
was performed (Madan-Khetarpal et al 2015 ACMG Abstract)20.  The results suggest that when a 
patient’s clinical presentation is indicative of a specific genetic condition, single gene or gene 
panel testing is appropriate.  However, when the genetic etiology of a patient’s condition is not 
obvious, WES/TES as a first-line test might be the most cost effective option.  This study 
compared patients whose initial genetics evaluation occurred before 2012 to those whose initial 
genetics evaluation occurred after 2012.  WES/TES was not generally offered clinically prior to 
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2012, therefore, those patients tended to have a longer diagnostic odyssey before being offered 
exome sequencing.  Diagnoses were made in 39.2% of cases overall and there was no difference 
in the diagnosis rate among both groups. The cost of diagnostic testing, however, was 
significantly different, with the group before 2012 spending an average of $15000 prior to 
receiving WES and those after 2012 spending an average of $7000 (Madan-Khetarpal et al 2015 
ACMG Abstract)20.   
Since the patients in this study were receiving services over different time periods, it is 
difficult to directly compare costs as technological improvements alone can lead to decreased 
costs.  Of note, however, the increased availability of WES/TES led to a reduction in the number 
of genetic tests ordered.  Those patients with an initial genetic evaluation before 2012 received 
an average of 4.1 single gene tests and 1.2 gene panels whereas, those with an initial genetic 
evaluation in 2012 or later received an average of 1.5 single gene tests and 0.64 gene panels.  
This analysis does not account for possible reductions in specialist consultations, biochemical 
testing, radiological assessments, cardiology assessments or neurology assessments, which can 
significantly impact costs as well.  The cost-benefit analysis, therefore, is likely an underestimate 
(Madan-Khetarpal et al 2015 ACMG Abstract)20.   
Similarly, another recent study found that 48% of patients who received WES had at least 
four prior genetic tests. In 3 out of their 40 cases, more than 10 genetic tests were performed, 
with a combined cost greater than that of WES17.  In a 2014 study of children with undiagnosed 
neurodevelopmental disorders, the diagnostic rate for WES was 40% and the average cost of 
negative testing for all patients prior to receiving WES was ~$19,000.  The investigators 
determined that for WES to be cost effective as a first-line test for these patients, the cost of 
testing should be under $7600 per family22.  However, the cost of delaying WES testing does not 
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account for any non-genetic testing related costs such as CT/MRI scans, biochemical tests, or 
skin/muscle biopsies.  It also does not account for the potentially increased detection rate that is 
likely to result from using WES as a first line test. 
7.1.2 Utility of whole exome sequencing 
WES has been increasingly used clinically when the suspected condition is genetically 
heterogeneous or the underlying genetic cause is unclear15.  Because WES is the most 
comprehensive and unbiased genetic test currently available clinically, it is particularly useful for 
diagnosing rare Mendelian disorders or uncovering complex mutation patterns by sequencing 
thousands of genes at once. The utility of the unbiased approached afforded by WES has been 
highlighted in a number of recent retrospective studies.  These studies revealed a diagnostic rate 
of 25-35%15–19 in which 37-41% of confirmed cases uncovered by WES were due to de novo 
autosomal dominant variants, meaning family history would not have provided clues to a 
diagnosis 15,19.  Importantly, 3-4.6% of confirmed cases were found to harbor pathogenic variants 
in two or more different genes and 29-58% of the total pathogenic variants uncovered had not 
been previously reported15,19,21.  Furthermore, WES identified mutations in genes known to be 
associated with genetic conditions but had not been suspected due either to genetic heterogeneity 
or an atypical presentation21.  These numbers suggest that traditional genetics approaches of 
single gene and gene panel testing were unlikely to determine the genetic basis for most of the 
cases included in these studies.   A recent prospective study found that in a cohort of infants 
whose clinical presentation suggests a monogenic disorder of non-obvious etiology, 57% were 
diagnosed by WES as a first-line test compared to 13.8% who received standard testing68, 
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suggesting marked utility for WES in this population as a first line test rather than test of last 
resort. 
Other studies have shown the ability of WES to detect pathogenic variants in a wide 
range of conditions including but not limited to neurodevelopmental disorders22,69, intellectual 
disability70, deafness15, skeletal dysplasias25, limb-girdle muscular dystrophy26, and retinal 
dystrophies27.  As more studies emerge detailing the utility and cost effectiveness of WES, 
insurance coverage may become less of a barrier to testing.   As of February 2016, 75 CHP 
patients received WES and 319 have received TES with an average of 8.4 WES/TES patients 
counseled per month (Internal Communication).  As access to WES increases, extensive results 
curation and lengthy counseling sessions of 2-3 hours will become untenable.  By developing 
targeted exome sequencing, which only focuses on variants in genes that could be related to the 
patient’s clinical presentation, CHP has drastically reduced the amount time required to counsel 
patients receiving TES.  However, with the bulk of the counseling provided during results 
disclosure, parents often come in to the session with a basic understanding of genetics, but with 
limited to absent knowledge about more complex genetics concepts such as exome sequencing.  
Trying to understand both new, complex genetics concepts along with their child’s specific 
results can be overwhelming.  By providing basic materials when TES testing is initially offered, 
parents can learn about genetics and the test itself while waiting for the results, which may help 
lower the anxiety level of parents and reduce the time needed for results disclosure. 
7.1.3 Cultural perceptions of exome sequencing  
Attitudes towards genetic testing in general have been shown to vary among different 
cultures7,8,71–75, which can alter an individual’s perception of the risks and benefits of pursing 
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testing.  One of the limitations of this current study is the lack of cultural diversity represented 
since effective genetic counseling requires an understanding of how risks and benefits are 
framed. Additionally, there is limited research available on the manner in which cultural context 
specifically alters the perception of whole exome or whole genome sequencing.  One recent 
study, however, did compare the perceptions of whole genome sequencing for research among 
African Americans and non-African Americans through the use of focus groups7,8.  
The majority of participants in both groups voiced interest in receiving at least some 
exome sequencing results and saw the benefit in the ability to be proactive upon finding 
actionable results7,8. Interestingly, the two groups displayed different temporal orientations when 
describing where this benefit is expected.  The African American group was oriented more 
towards the present, focusing on potential short term health benefits as well as potential 
immediate psychosocial impacts. The non-African American group was instead oriented towards 
the future, focusing on the ability for results to help with long term planning. Furthermore, 
African American participants were also more community-focused than individualistic in 
decision making and considering the potential impact of their results compared to non-African 
Americans.  When contemplating hypothetical actionable results, however, African American 
individuals raised concerns about a lack of health care access impacting their ability to follow-up 
and about the potential to overwhelm an already stressful life whereas non-African Americans 
did not display the same hesitation. Additionally, non-African Americans expected their health 
care providers to be fully aware of their results and actively involved in their continued care. 
While some African American participants, on the other hand, voiced concerns for law 
enforcement accessing their genetic information or misuse of this information by the health care 
system, preferring the ability to pursue this type of testing privately, outside of the system7,8.  
 70 
Distrust of the health care system and lack of health care access can be major barriers in the 
decision to pursue genetic testing. 
It is not clear how generalizable these study results are since the sample size was small 
and there may have been significant differences between the two groups other than ethnicity, 
such as education level and health status.  Additionally, the study focused on exome sequencing 
in a research setting rather than a clinical setting.  However, the responses highlight the potential 
for an individual’s background to frame their perception of genetic testing and the importance for 
genetic counselors to be aware of these differences.  While these studies focused on the 
differences among African American and predominantly Caucasian individuals, members of 
other ethnic backgrounds are likely to display their own unique perceptions of genetic testing and 
exome sequencing.  Therefore, any counseling strategy aimed at the general population should 
take into account the various cultural contexts present in the population. 
7.2 SURVEY WIDER POPULATION OF INDIVIDUALS WHO RECEIVED EXOME 
SEQUENCING RESULTS 
While many parents in this present study described feeling overwhelmed when trying to learn 
about general genetics concepts and their child’s specific results during the same consultation, 
some parents disclosed that they were not overwhelmed and, rather, appreciated receiving all the 
information at once.  Since the population size was not powered for statistical significance, a 
larger survey of parents’ preferences should be performed prior to developing materials or 
altering counseling strategies.  A survey of parents whose children have completed TES testing 
should address parents’ desire for information on general genetics prior to the results disclosure 
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and what information, if any, should be included.  Furthermore, as described above, perceptions 
and concerns regarding genetic testing vary across cultures.  Therefore, the study population 
should encompass diverse backgrounds in terms of ethnicity, gender, educational and 
socioeconomic backgrounds.  
7.3 DEVELOP TES EDUCATIONAL MATERIALS 
If the survey demonstrates that a majority of parents prefer more information about TES before 
the results disclosure, educational materials would be developed in collaboration with 
geneticists, genetic counselors, patients/parents, and community partners to ensure cultural 
sensitivity as well as accurate and understandable explanations of complex concepts, such as 
variants of uncertain significance (VUS).  The process would follow a similar overall approach 
taken by Sanderson et al when developing an online educational video for WGS76 and begin with 
a review of existing publically available educational resources, determining their strengths and 
weakness and where improvements can be made. 
The initial development would focus on written materials since, compared to videos, they 
are more economical, easier to update, and do not limit access to those with specific equipment.  
Moreover, prior studies of health related educational resources have not demonstrated any 
benefit to video over written materials76.  However, this approach would potentially limit access 
to illiterate and non-English speakers.  The content would be directed by input from the 
stakeholders mentioned above as well as by results from the preliminary survey. Likely topics to 
incorporate include  
 
 72 
1. An introduction to genes, chromosomes, proteins with a definition of the exome 
2. An overview of WES/TES including method, purpose, benefits, and limitations 
(diagnosis rate, types of conditions not covered, wait time, insurance barriers). 
3. A discussion of the different types of possible results, their interpretations, and potential 
psychosocial reactions to each type of result  
Focus groups should be conducted with members of the aforementioned stakeholder groups 
following the initial development of the written educational resource to evaluate content, design, 
readability, and accuracy.  The materials would be amended as directed by the results of the 
focus groups.  Once a final product is created, these materials would be distributed to patients 
undergoing TES and/or their parents following the brief introduction to TES that is currently 
provided by geneticists or genetic counselors at CHP.  The quality of the materials would then be 
evaluated based on patient/parent satisfaction and knowledge. 
7.4 EVALUATE SATISFACTION WITH AND EFFICACY OF EDUCATIONAL 
MATERIALS 
A survey would be conducted to determine participants’ overall satisfaction with the educational 
materials, assessing areas such as language/word choice, relevance of content, organization, 
amount of information, and clarity of information.  Participants would also complete a pre-test 
prior to receiving the educational materials and a post-test prior to results disclosure in order to 
assess how much knowledge was gained and retained.  Since participants in this current study 
seemed to misunderstand the interpretation of VUSs and the meaning of the different types of 
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possible results, questions should be particularly focused in these areas in addition to areas of 
more basic genetics. 
As exome sequencing technology continues to develop making testing more affordable 
and as insurance companies become more accepting, WES/WGS will likley not be limited to a 
small number of rare, esoteric cases.  Rather, wider applicability of exome sequencing has been 
proposed in the prenatal setting77,78, in newborn screening79,80, to diagnose complex conditions, 
or to provide pre-symptomatic screening in healthy individuals.  As the applicability of 
WES/WGS expands, so too will the types of providers offering this testing.  If WES/WGS 
begins to be offered by non-genetics professionals, patients will increasingly benefit from the 
availability of educational materials describing exome sequencing along with its benefits and 
limitations clearly and accurately. 
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APPENDIX A: IRB APPROVAL LETTER 
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APPENDIX B: PARTICIPANT RECRUITMENT SCRIPT (TELEPHONE) 
Hello, 
(Marianne McGuire intoduces herself) 
I am contacting you to let you know about an opportunity to participate in research here at 
Children’s. (ask if now is a good time to talk or if they prefer that you call them at a later time. If 
later, arrange a time.)  The purpose of this research study is to better understand the experiences 
of parents whose child has been tested using targeted exome sequencing. We want to learn more 
about these expereinces so we can improve our approach to offering this testing. To accomplish 
this, Bess Wayburn, a genetic counseling student, will be interviewing parents whose children 
have received results from targeted exome testing through the Medical Genetics Department at 
Children’s Hospital of Pittsburgh.  The researchers only be told of your child’s results status (i.e. 
positve, negative, or uncertain), not the specific results of his/her testing. Those parents who 
choose to participate will be asked to complete an approximately 1 hour telephone or in person 
interview with Bess as the main investigator for the study. During the interview, those who 
choose to do the study will be asked questions about their thoughts and opinions on the 
information they were given before deciding to have the testing done, how well they thought 
they understood that information and whether they could ask questions freely before making a 
decision. They will also be asked about how things went when the results were given to them. 
Would you be interested in learning more about this research study? 
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If yes: May I provide Bess with your contact information so she can discuss the details of 
this study with you further? 
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APPENDIX C: PARTICIPANT VERBAL CONSENT SCRIPT (TELEPHONE) 
Hello, my name is Bess Wayburn, a Genetic Counseling student working on the study entitled 
“Psychosocial impact of targeted exome sequencing of chronically ill children”.  Marianne 
McGuire, a genetic counselor from Children’s Hospital of Pittsburgh, referred you to my study.  
Are you interested in hearing more about it? 
You are being asked to participate in this research study because your child received 
results from a targeted exome sequencing test. The purpose of this research study is to better 
understand the experiences of parents with the entire testing process so we may improve the way 
we offer this type of testing. To accomplish this, we will be interviewing parents whose children 
have received positive, negative, or uncertain results from targeted exome testing through the 
Medical Genetics Department at Children’s Hospital of Pittsburgh.  
Participants are asked to complete an approximately 1 hour telephone or in person 
interview with the main investigator in the study. The interview will ask about thoughts and 
opinions on the information parents were given before deciding to have the testing done, how 
well they thought they understood that information and whether they could ask questions freely 
before making a decision. They will also be asked about how things went when the results were 
given to them. Interviews will be audio recorded for transcription. Identifying information such 
as your name will be removed from the transcript.  
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All responses to the interview are confidential and responses will be stored in a secure 
manner. Personal password-protected computers and a locked file cabinet will be used to store 
records. Research records for this study will be stored indefinitely without information that can 
be linked to participants’ identities.  It is possible that in the future, other investigators interested 
in performing similar research will request access to data or materials from this study.  If data is 
shared with other investigators, they will not be able to link the data to the participants’ identities 
in any way. 
While your participation may not directly benefit you, information gathered through the 
study will be used for improving our counseling process for targeted exome sequencing testing. 
This knowledge may benefit patients who undergo this testing in the future by allowing health 
professionals to design a more patient-focused testing process.  You will not receive any 
payment for your participation and there is no cost to participate. 
In unusual cases, in response to a court order, the investigators may be required to release 
identifiable information (which may include your identifiable medical information) related to 
your participation in this research study.  If investigators learn that you or someone with whom 
you are involved is in serious danger or potential harm, they will need to inform, as required by 
Pennsylvania law, the appropriate agencies. No medical procedures will be performed in this 
study but if you believe that the research procedures have resulted in injury to you, contact the 
Principle Investigator immediately.  Emergency medical treatment for injuries solely and directly 
related to your participation in this research study will be provided to you by the hospitals of 
UPMC.  Your insurance provider may be billed for the costs of this emergency treatment, but 
none of those costs will be charged directly to you.  If your research-related injury requires 
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medical care beyond this emergency treatment, you will be responsible for the costs of this 
follow-up care.  At this time, there is no plan for any additional financial compensation. 
Your participation is voluntary and you may withdraw from this project at any time. Any 
answers recorded in the interview prior to withdrawal will remain part of the study. Your 
decision to participate or not participate will not affect your current or future relationship with 
the University of Pittsburgh Medical Center or the University of Pittsburgh.  
You are encouraged to ask questions, voice concerns or complaints about any aspect of 
this research study during the course of this study, and future questions, concerns or complaints 
will be answered by a qualified individual, by the Principal Investigator, Bess Wayburn at ___, 
or co-investigator Catherine Walsh Vockley at 412-692-7349. You may contact the Human 
Subjects Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-2668) to 
discuss problems, concerns, and questions; obtain information; offer input; or discuss situations 
in the event that the research team is unavailable. 
 
Do you have any questions about the study or the information I just went over? 
Are you interested in participating in this study? 
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APPENDIX D: PARTICIPANT INTERVIEW GUIDE 
Date: ___/___/____  
Study participant’s ID: ______________________________  
Interview method: ____ Phone ____ In-person  
Parent: ____ Mom ____ Dad  
Parental age: _____  
Education level of parent: High school degree ____ Associate’s degree ____ Bachelor’s  
degree ____ Master’s degree ____ Doctoral degree ____ Other 
_______________  
Child’s symptoms:  
What testing did [child] receive prior to TES?: 
How old is [child]? _____  
Was [child] your first-born child? _____If other children: What are the ages of the other children 
____________ 
Are other children in the family affected? 
Prior to testing 
Tell me about yourself (and your family) 
Tell me about how you first found out about your child’s condition. 
People have many ideas about what causes birth defects or health problems. What were your 
initial thoughts about what may have caused your child’s condition?  Have those thoughts 
changed and if so, how?  
Tell me about your experience since the onset of your child’s condition. 
• Prompts (if necessary) 
o How many other specialists had you seen prior to or along with Genetics? 
o What sorts of other tests/treatments had already been performed prior to TES? 
Please describe your experience meeting with the geneticist or genetic counselor to discuss your 
child’s condition prior to first being offered TES 
• Prompts (if necessary) 
o What did you learn from the geneticist, if applicable? 
o What did you learn from the genetic counselor, if applicable?  
o Is there anything else that you would have liked to have learned from them? 
 
 81 
Informed consent process 
When you were first told about TES, what was the explanation given for providing your child 
with this test?  
How was TES described to you?  
What was your understanding of the goals of this test? 
What information, in hindsight, was missing that you wish you had been given?  
Did you have any questions that you do not think were answered, or do you have more  
questions now (address these) 
What advice would you give to the person who discussed the test with you prior to testing in 
order to help other families who are considering the same test? 
How would you describe this test to other families? 
 
Thoughts/assumptions prior to results disclosure 
After the testing process began, what were your expectations were for the results? 
• Prompts (if necessary) 
o How definitive the results would be 
o How long test would take 
o How paying for the test would work 
What questions or concerns, if any, did you have after the testing process began? 
What were your thoughts about the possibility of not getting an answer from this test?   
What were your thoughts about the possibility of getting an uncertain result from this test? 
Did you and others discuss the testing while it was being done?  If so, please describe for me the 
conversations about the test that took place between you and your partner and between you and 
other family members or any other important people in your life?  
How was the waiting time for you to get the results once the test was started?  Is there anything 
that the geneticist/genetic counselor could have done to assist you during that time? 
 
Experience with results disclosure 
When you think of your child’s results, what is the first thing that comes to your mind?   
What is your interpretation of what the test results mean?   
Describe your experience with receiving your results. 
• Prompts (if necessary) 
o Did you get information you hoped to get? 
o How did you react to the information? 
o How did it make you feel? 
o Were you given enough information to understand their meaning?  Were you 
given too much information? 
How did the experience match your understanding and expectations? 
How did the experience differ from your understanding and expectations?  
What questions, if any, did you ask at the time?  
 
Post results reflections 
What are some of the positives, if any, of the genetic testing process you went through?  
What were some of the negatives, if any?  
How has the test result impacted your perception of your child’s future wellbeing? 
How have the results impacted your child’s ongoing medical care? 
How has the test result impacted the important relationships in your life? 
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• Prompts (if necessary) 
o Will you share/have you shared your results with extended family members or 
other important people in your life? What are the reasons for your decision?   
o What is your understanding of the implications for other family members? 
How has this experience affected your thoughts on future family planning?  
When it comes to the experience of genetic testing, what I have missed that you would like to 
share?  
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